Laparoscopic hysterectomy in benign gynaecological conditions. Outcomes after total laparoscopic hysterectomy and laparoscopic supracervical hysterectomy, a comparison of surgical procedures by Berner, Espen
  
Laparoscopic hysterectomy in benign gynaecological conditions 
Outcomes after total laparoscopic hysterectomy and laparoscopic  
supracervical hysterectomy, a comparison of surgical procedures  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PhD thesis by 
Espen Berner, MD 
2014 
 
Department of Gynaecology 
Oslo University Hospital, Ullevål  
and 
University of Oslo,  
Faculty of Medicine 
Norway 
 
        
 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3 
TABLE OF CONTENTS 
 
1. Acknowledgements…………………………………………………………….   5  
2. List of papers…………………………………………………………….   7 
3. Abbreviations…………………………………………………………….   9 
4. Summary…………...…………………………………………………….. 11 
5. Introduction……………………………………………………………... 15 
5.1.  Definitions and methods of hysterectomy..............................…. 15 
5.2.  Clinical considerations and controversies  
in methods of hysterectomy…………………………………….. 17  
6. Aims of the thesis………………………………………………………… 23 
7. Materials and methods………………………………………………….. 25 
7.1.  Approvals……………………………………………………… 25  
7.2.  Design…………………………………………………………. 25 
7.3.  Patient selection……………………………………………….. 25 
7.3.1. Enrollment and study populations…………………………….. 25 
7.3.2. Inclusion / exclusion criteria………………………………… . 26 
7.4.  Description of inventional procedures………………………… 27 
7.5.  Collection of data and outcome measures…………………….. 29 
7.6.  Randomisation and concealed allocated treatment……………. 31 
7.7.  Statistics……………………………………………………….. 31 
7.7.1 Test power…………………………………………………….. 31 
7.7.2 Statistical analysis…………………………………………….. 32 
7.8.  Ethics………………………………………………………….. 32 
 4 
8. Summary of results……………………………………………………… 35 
8.1.  Laparoscopic Supracervical Hysterectomy Performed  
With and Without Excision of the Endocervix:  
A Randomized Controlled Trial (Paper 1)…………………….. 35 
8.2.  Pelvic Pain and Patient Satisfaction after Laparoscopic  
  Supracervical Hysterectomy, Prospecitve Trial (Paper 2)…….. 37 
8.3.  Pain reduction after total laparoscopic hysterectomy and  
 laparoscopic supracervical hysterectomy among women  
 with dysmenorrhea: a randomised controlled trial (Paper 3)….. 38 
8.4.  A comparison of the trials in the PhD thesis…………………... 42 
9. Discussion……………………………………………………………… ... 45 
9.1.  Patient selection……………………………………………….. 45 
9.2.  Methodological considerations……………………………...…. 46 
9.2.1  Study design…………………………………………………………. 46 
9.2.2 Outcome measures…………………………………………………… 47 
9.3.  Interpretation of the results………………………………….…. 48 
10. Conclusions and perspectives…………………………………………… 51 
10.1. Conclusions……………………………………………………. 51 
10.2. Perspectives……………………………………………………. 52 
11. Errata……………………………………………………………………. 55 
12. References……………………………………………………………….. 57 
13. Papers I-III………………………………………………………………. 77 
 
 
 
 
 
 
 
 5 
1. ACKNOWLEDGEMENTS 
The present work was carried out at Department of Gynaecology, Oslo 
University Hospital, Ullevål and the Faculty of Medicine, University of Oslo from 
2008-2014.  
 I am greatly indebted to my two supervisors Associated Professor Marit Lieng 
and Professor Erik Qvigstad, who have guided me throughout the process. I am 
especially grateful to Marit for the idea to the project and the initial study protocols 
drafted by her. The cooperation with my supervisors has been joyful. I appreciate the 
way the both of you have supported me, encouraged me to present our results abroad 
and introduced me to important and interesting colleagues in Europe and the US. I am 
grateful for this opportunity to develop as an academic gynaecologist and as a person. 
 I want to thank Bjørn Busund, Head of Department of Gynaecology and Anny 
Spydslaug, Head of the unit of general Gynaecology for believing in and providing the 
financial support for this project. I am grateful to my co-author and inspiring colleague 
Anton Langebrekke. Through his constant effort in developing the endoscopic 
expertise at our department is Anton an essential contributor for the basis of this thesis. 
I am also thankful to my co-author Anne Kristina Myrvold at Department of Pathology 
for her contribution, especially for analysing all the specimens in the project. I want to 
thank Professor Leiv Sandvik at Department of Clinical Research for his statistical 
recommendations during the planning of the trials. I am also grateful for the effort 
provided by Olav Istre and Jan Bye during the development and production of the 
Lapcone-electrode. I want to thank Annetine Staff, Head of the Research Group of 
Obstetrics and Gynaecology for advices regarding local approvals and application for 
the ethical committee. 
 Likewise, I want to thank the consultants at the unit of general Gynaecology for 
treating the study participants and devotedly performing the allocated procedures in 
the trials. You all have an essential part of this thesis. I am grateful to the nurses at the 
operating theatre for their dedicated contribution in the project. I also want to thank the 
secretaries and nurses at the outpatient clinic and the gynaecological coordinating 
office for their flexibility and support regarding logistics of the study participants. 
 6 
Especially, I want to thank Marit Dalanger Vikdal for her patience at the outpatient 
clinic during the inclusion and follow up of the study participants. I am grateful for the 
assistance from the staff at the Medical Library at Ullevål during the final preparation 
of the thesis.   
 I also want to thank all my excellent colleagues at both the Department of 
Gynaecology and Obstetrics for their support and for providing women eligible for 
study participation.  A special thank to all the women who have been included in the 
studies. This thesis would not have been possible without your participation.  
The work with this thesis has been like an inspiring journey with new insight, 
both academically and personally. I am grateful to Anne Elisabeth Bjerkreim for her 
companionship during this process and for stimulating discussions regarding research 
and women health. Finally, I want to thank my children Nora and Sondre for keeping 
me young at heart.  
 
       Espen Berner, November 2014. 
 
 7 
 
 
2. LIST OF PAPERS 
 
 
Paper I:  
Espen Berner, Erik Qvigstad, Anton Langebrekke, Marit Lieng. Laparoscopic 
Supracervical Hysterectomy Performed With and Without Excision of the Endocervix: 
A Randomized Controlled Trial. J Minim Inv Gynecol 2013; 20: 368-75. 
 
Paper II: 
Espen Berner, Erik Qvigstad, Anne Kristina Myrvold, Marit Lieng. Pelvic Pain and 
Patient Satisfaction after Laparoscopic Supracervical Hysterectomy, Prospective Trial. 
J Minim Invasive Gynecol 2014; 21: 406-411. 
 
Paper III: 
Espen Berner, Erik Qvigstad, Anne Kristina Myrvold, Marit Lieng. Pain reduction 
after total laparoscopic hysterectomy and laparoscopic supracervical hysterectomy 
among women with dysmenorrhea: a randomised controlled trial.  
British Journal of Obstetrics & Gynaecology 2014, Submitted. 
 
 8 
 
 9 
 
3. ABBREVIATIONS 
 
AH  Abdominal hysterectomy 
AUB  Abnormal uterine bleeding 
BMI  Body mass index 
EFI  Endometriosis Fertility Index 
FDA  U.S. Food and Drug Administration  
Hb  Hemoglobin 
LAVH  Laparoscopically assisted vaginal hysterectomy  
LEEP  Loop electrosurgical excision procedure 
LH  Laparoscopic hysterectomy 
LSH  Laparoscopic supracervical hysterectomy 
MIS  Minimal invasive surgery 
OUS  Oslo University Hospital  
POP  Pelvic organ prolapse 
POP-Q Pelvic Organ Prolapse-Quantification  
Qol  Quality of life 
RCT  Randomised controlled trial 
SAH  Supracervical abdominal hysterectomy 
SD  Standard deviation 
SF-36  Short Form 36 
SPSS  Statistical Package for the Social Sciences 
TAH  Total abdominal hysterectomy 
TLH  Total laparoscopic hysterectomy 
VH  Vaginal hysterectomy 
VAS  Visual analogue scale 
 10 
 
 
 11 
4. SUMMARY  
 
 There has been a continued debate for decades regarding methods of 
hysterectomy. The disagreement has both been related to the surgical approach and the 
removal of cervix in women suffering from benign conditions. After the 
implementation of the laparoscopic approach, the rate of supracervical hysterectomy 
has increased. The preference of total laparoscopic hysterectomy (TLH) or 
laparoscopic supracervical hysterectomy (LSH) follows the corresponding discussion 
as for abdominal hysterectomy. Arguments in favor of LSH have been a reduced risk 
of complications and a more rapid recovery without compromising the long-term 
outcome compared to TLH. In contrast, a risk of vaginal bleeding and pelvic pain after 
LSH has been documented. Cervical stump symptoms after a supracervical 
hysterectomy might cause patient distress and repeated surgery. In addition, the risk of 
complication caused by tissue extraction using the morcellator during the LSH-
procedure has become the focus of this debate, recently. 
 Inadequate amputation of the cervix during LSH may cause remnant 
endometrial tissue in the upper cervix. Consequently, a modification of the surgical 
technique might reduce the occurrence of vaginal bleeding after this procedure. For 
this purpose, we developed a monopolar device for a reverse loop electrosurgical 
excision procedure (LEEP) of the endocervix during LSH.  
The risk of a persistent cyclic pelvic pain after LSH has also been recognized. 
Especially, this risk is evident in women with endometriosis. Therefore, various 
gynecologists have claimed that supracervical hysterectomy should not be performed 
in women with endometriosis, pelvic pain or dysmenorrhea. Other gynecologists state 
that endometriosis and pelvic pain should not be contraindications for performing 
supracervical hysterectomy, unless leaving the cervix compromises the removal of 
endometriosis.   
 In the decision of performing a total or supracervical hysterectomy in minimal 
invasive surgery (MIS), the benefits of LSH must be weighed up against the risk of 
complications and persistent cervical stump symptoms after the procedure. 
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Unfortunately, there is a lack of prospective randomised trials (RCT) to evaluate 
outcomes after different methods of MIS hysterectomy.  
The persistent debate regarding methods of MIS in hysterectomy encouraged us 
to carry out the trials included in this PhD thesis. The aims of this thesis were to 
explore and compare the outcomes of different techniques of laparoscopic 
hysterectomy. Firstly, we intended to compare the occurrence of vaginal bleeding and 
patient satisfaction 12 months after LSH performed with and without the use of a 
reverse LEEP of the endocervix (Paper 1). Secondly, we wanted to evaluate the 
occurrence, intensity and reduction of cyclic pelvic pain and patient satisfaction 12 
months after LSH (Paper 2). In particular, we aimed for a subgroup analysis of cyclic 
pelvic pain in study participants with or without perioperative detection of 
endometriosis and in women with or without histological confirmed adenomyosis in 
this trial. Finally, we wanted to compare cyclic pelvic pain, patient satisfaction and 
quality of life 12 months after TLH and LSH, respectively (Paper 3). An additional 
subgroup analysis of women with or without perioperative detection of endometriosis 
and in women with or without histological confirmed adenomyosis was conducted in 
this trial as well.   
To achieve the aims mentioned above, two blinded RCTs were conducted. In 
addition, a prospective observational study was performed. Premenopausal women 
referred for hysterectomy on the basis of a benign condition were eligible for study 
recruitment. In the first RCT, the study participants were either allocated to the 
standardized LSH operative technique at our department or LSH performed with a 
laparoscopic LEEP of the endocervix in a reverse cone pattern. In the second RCT, the 
study participants were randomised to either TLH or LSH. In this RCT, the LSH was 
performed with the standardized operative technique without excision of the 
endocervix. In both RCTs, the allocated treatment was concealed for study participants 
throughout the 12 months follow up period. The observational trial was recruited 
among study participants from the first RCT and included only women with 
preoperative cyclic pelvic pain treated by LSH.  
During planning of the trials, a power analysis for the primary outcome was 
conducted for each of the RCTs. The test power was set to be 90 % and the level of 
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significance was 0.05. In accordance to the results of the power calculations, 140 and 
62 women were included in the two trials, respectively. The data of the two RCTs 
were analyzed according to the principle of intention to treat. The prospective 
observational was an open trial of women treated by LSH. Therefore, this trial was 
analyzed per protocol.  
This PhD thesis concludes that an additional reverse LEEP of the endocervix 
during LSH do not reduce bleeding 12 months after the procedure compared to the 
standard LSH-technique. Vaginal bleeding after LSH occurs quite frequently, but the 
bleeding episodes are minor and do not affect patient satisfaction.  
Secondly, this PhD thesis confirms a very high patient satisfaction after LSH 
and TLH, respectively. There is a significant and comparable improvement in Quality 
of life (Qol) 12 months after both procedures. There are no differences in patient 
satisfaction and Qol 12 months after TLH compared to LSH.   
Finally, the PhD thesis demonstrates that cyclic pelvic pain is reduced to a 
minimum 12 months after LSH and TLH, respectively. There is no difference in cyclic 
pelvic pain 12 months after TLH compared to after LSH. Women with minimal, mild 
or moderate endometriosis detected and treated during the procedures, should 
anticipate the same reduction of cyclic pelvic pain 12 months after LSH or TLH 
compared to women without endometriosis. The same pattern should be anticipated for 
women with adenomyosis confirmed in the specimen from hysterectomy compared to 
women without adenomyosis in specimen after TLH and LSH, respectively.  
The findings in this PhD will be used to individualize the preoperative 
counselling before MIS hysterectomy in women with benign conditions. If vaginal 
hysterectomy is not feasible, the laparoscopic approach is recommended. The method 
of LSH and TLH appears to demonstrate comparable clinical outcomes, also in women 
with minimal, mild or moderate endometriosis and in women with adenomyosis. If 
there are no documented differences in the essential outcomes in benign conditions, 
the safest procedure should be preferred. In addition, patient preferences must also 
always be taken into account. To evaluate the benefits and risks of the treatment 
options, an individual risk analysis should be presented to the women, preoperatively. 
In spite of the current recommendations, abdominal hysterectomy continues to be a 
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frequently used method worldwide. Compared to LSH, the TLH-technique requires 
more advanced laparoscopic skills. Therefore, to safely accomplish a total 
hysterectomy in women with fibroids, laparotomy might be the only feasible method 
for many gynaecologists. Consequently, to avoid laparotomy in selected women, the 
gynaecologist should consider performing LSH. Therefore, a more extent 
recommendation of LSH might reduce abdominal hysterectomy worldwide.  
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5. INTRODUCTION 
 
5.1 Definitions and methods of hysterectomy 
 Hysterectomy is defined as removal of the uterus.1;2 This can be performed with 
and without additional removal the ovaries and/or fallopian tubes. A total 
hysterectomy is defined as removal of the complete uterus including the cervix. In 
contrast, a supracervical hysterectomy is classified as removal of the uterus with 
preservation of the cervix. This method is also named subtotal hysterectomy or 
supravaginal uterus amputation.1  
 There are three major methods of conducting hysterectomy, named by their 
surgical approach.1;3-5 Sometimes, a combination of two approaches is preformed. 
Hysterectomy has traditionally been conducted by abdominal hysterectomy (AH).5-13 
This is performed through laparotomy with midline (lower or full-length) or lower 
transversal (eponym: Pfannenstiel) incision. AH may be carried out as a total 
abdominal hysterectomy (TAH) or supracervical abdominal hysterectomy (SAH).7;14-24 
In vaginal hysterectomy (VH) the entire procedure is performed by a vaginal 
approach.3-5;8;25-27 Consequently, this method leaves no visible scar on the abdomen or 
external genitalia. For all practical reasons, VH is only performed as a total 
hysterectomy. The third and most recent approach is the laparoscopic hysterectomy 
(LH).3;4;9;28-34 This method is equivalent to the AH, performed laparoscopically. 
Therefore, LH may also be conducted as a total or supracervical hysterectomy.28;33;35 
Throughout the implementation of the laparoscopic technique the last 20 years, there 
have been several names and definitions of this method to distinguish the different 
proceedings of the LH.2;28;33-43 The specific names rose to describe whether the entire 
method was performed laparoscopically or if it was conducted in a combination with 
VH.2;5;9;43-46  The names and abbreviations for LH used in this thesis are total 
laparoscopic hysterectomy (TLH), laparoscopically assisted vaginal hysterectomy 
(LAVH) and laparoscopic supracervical hysterectomy (LSH). The LSH-procedure is 
also described in the literature as classic intrafacial supracervical hysterectomy (CISH) 
technique and also known by the abbreviation LASH.37;40;47  
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 In this thesis, TLH is defined as the entire procedure is performed 
laparoscopically and the uterus is removed through the vagina. The main difference 
between LAVH and TLH is related to the closure of the vaginal cuff. The LAVH-
procedure starts out as a laparoscopic procedure and the specimen is removed through 
the vagina. In LAVH, the closing of the vaginal cuff is always performed vaginally. A 
supplementary dissection and/or ligation of the uterine vessels may be conducted 
through the vaginal approach as well. For LSH, the entire procedure is performed 
laparoscopically. The specimen is then removed through the small incisions of the 
abdominal wall. After amputating the cervix during the LSH-procedure, a morcellator 
has often been used.37;38;40;48-52 The morcellator is an electromechanical device 
designed to fragment the specimen. Thereby, the morcellator makes it possible to 
remove the smaller tissue through the incisions of the abdomen.  
To facilitate the abdominal incisions (5-20 millimeter) in laparoscopic 
procedures, medical devices named trochars are used.38;53 Normally, four incisions and 
trochars are used to perform a LH. The trochars are placed trans-abdominally for 
optimal visualization and presentation of the operating field during the procedure. The 
trochars are placed according to the individual preference of the operating surgeon. 
The typical trochar placements in LH are one in the umbilicus for use of the 
laparoscopic camera, one trochar in each lower quadrant of the abdomen and one 
placed in midline supra-pubically.38 In recent years, flexible gel-trochars have been 
developed for single-incision use through the umbilicus.53 This leaves no visual 
abdominal scars except for the intra-umbilical incision.  
For the last decades, the robotic assisted LH has also become an option.54-58 
This procedure is classified as a variation of the laparoscopic approach, useful in 
selected cases. 54-58 The radical hysterectomy (eponyms: Wertheim hysterectomy or 
Wertheim-Meigs operation) is a last method for hysterectomy.1 This technique is used 
in women suffering from oncological conditions. Therefore, this method is not covered 
further in this thesis of hysterectomy in benign gynecological disorders.  
 
 17 
5.2 Clinical considerations and controversies in methods of hysterectomy 
The technique for hysterectomy has been debated throughout the last century. 
The controversies have mostly been related to diversity in surgical approach and 
removal of the cervix.2;5;8;9;13;16;17;22;24;43;59-64 In benign gynecological conditions 
requiring hysterectomy, there is an indisputable recommendation to use minimal 
invasive surgery (MIS) and thereby to avoid the AH by laparotomy.2-5;8;63;65 If vaginal 
hysterectomy is not feasible, the laparoscopic approach is recommend.3-5;9;25;28;65 
However, the MIS techniques are not implemented completely. Consequently, AH 
continues to be frequently performed worldwide.6;9;11-13;42;66-70  
 The majority of hysterectomies include removal of the cervix, but the rate of 
supracervical hysterectomy has increased in women with benign conditions requiring 
hysterectomy.7;10;11;21;28;35;41;67;68;71-75 There are several randomised controlled trials 
(RCT) comparing outcomes of total and supracervical hysterectomy.14;17;19;21-24;28;35;76-
84 Most of these RCTs compare the TAH and SAH, table 1.14;17;19;21;23;24;77;80-82 There 
are only two RCTs comparing different MIS techniques of TLH, LAVH and LSH.78;79 
In addition, the trial by Thakar et al is the only RCT performed with appropriate 
blinding of the allocated treatment during treatment and follow up after the 
procedures.24  
 For the last decade, LSH has been a preferred method for hysterectomy in 
selected cases at our hospital.7;31;51;85;86 This procedure is performed in premenopausal 
women with benign conditions and no history of previous cervical dysplasia. LSH is 
associated with high patient satisfaction. This procedure is easier to perform and has a 
lower risk of complications and faster recovery after surgery compared to 
TLH.28;33;35;40;41;63;73;87-91 However, leaving the cervix during hysterectomy is 
debatable.3;4;16;28;29;31;33;34;43;48-50;60;92-99 The preference of TLH or LSH follows the 
corresponding discussion as for AH. The incidence of cervical cancer after 
supracervical hysterectomy is low in countries with routine cervical screening 
programs. This minor risk is no justification for removal of the cervix.22  
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Table 1: Randomised controlled trials comparing total and supracervical hysterectomy 
techniques. 
 
First author Year published n 
Follow up  
(months) 
Allocated treatments, 
compared 
Thakar R. 2002   20091 279
 12  
1081 TAH
2 versus SAH3 
Learman L.A. 2003 135 24 TAH versus SAH 
Gimbel H. 
Andersen L.1 
2003 
 20141 319
 12 
 601 TAH versus SAH 
Flory N. 2006 63 6-7 LAVH4 versus LSH5 
Morelli M. 2007 141 24 TLH6, versus LSH 
Gorleo F. 2008 105 36 TAH versus SAH 
Persson P. 2010    20131 179 
12 
1351 TAH, versus SAH 
Ellstrom M.A. 2010 132 12 TAH, LAVH, TLH and VH7 versus SAH and LSH 
Asnafi N. 2010 150 6 TAH, versus SAH 
1 Longterm follow up of the study population above. 
2 TAH = total abdominal hysterectomy 
3 SAH = supracervical abdominal hysterectomy 
4 LAVH = laparoscopically assisted vaginal hysterectomy 
5 LSH = laparoscopic supracervical hysterectomy 
6 TLH = total laparoscopic hysterectomy 
6 VH = vaginal hysterectomy 
 
  Several gynecologists have documented a risk of vaginal bleeding after LSH, 
table 2.31;38;71;94;97;99-105 Cervical stump symptoms after this procedure might cause 
patient distress and repeated surgery.31;95;97 Remnant endometrial tissue in the upper 
cervical canal has been claimed to be the main cause of recurrent bleeding episodes 
after LSH.71 Therefore, we worked out a promising modification of the surgical 
technique in order to reduce the occurrence of vaginal bleeding after the 
procedure.86;102 A monopolar device for reverse loop electrosurgical excision 
procedure (LEEP) during laparoscopy was developed. A pilot trial documented this 
LEEP device to be a quick and safe method for removal of the endocervix by a reverse 
cone during LSH.86 No previous RCT has reported upon the impact of different 
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surgical LSH techniques on occurrence of vaginal bleeding and patient satisfaction 
following the procedure. 
 
Table 2:  Clinical trials reporting vaginal bleeding after laparoscopic supracervical 
hysterectomy. 
 
First author Year published n 
Follow up 
(months) 
Bleeding  
(%) 
Richards S.R. 1995 41 16 10.0 
Donnez J. 1997 500 24 2.4 
van der Stege J.G. 1999 20 27 25.0 
Lyons T.L. 2000 236 - 1.3 
Zupi E. 2001 92 24 0 
Okaro O.E. 2001 70 66 11.4 
Milad M.P. 2001 27 - 3.7 
Ghomi A. 2005 67 3-15 19.0 
Lieng M. 2005 315 36 24.0 
Schmidt T.  2010 300 12 1.4-10.7 
Tchartchian G. 2013 1431 6-72 23.3 
Nouri K. 2013 173 36 5.2 
 
  There has also been documented a risk of persistent cyclic pelvic pain 
after LSH.31;34;35;95;97;106 Especially, this risk is recognized in women with 
endometriosis.31;95 Consequently, several authors have stated that supracervical 
hysterectomy should not be performed in women with endometriosis, pelvic pain or 
dysmenorrhea.34;35;60;95;97 Even at our department, there has been a shift recent years 
towards TLH in women suffering from these conditions (non-published data). This 
alteration has occurred despite there is no high quality evidence to demonstrate a 
superior result for total hysterectomy compared to supracervical hysterectomy for 
these women.28;35;78;79 Furthermore, some gynecologists conclude that endometriosis or 
pelvic pain should not be contraindications for performing supracervical hysterectomy, 
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unless leaving the cervix compromises the removal of endometriosis.28;35;78;79;90;96;107;108 
Therefore, in the debate of total or supracervical MIS hysterectomy, the benefits of 
LSH must be weighed up against the risk of complications and persistent cervical 
stump symptoms after the procedure.  
 Recently, there has also been an increasing focus on the use of the morcellator 
for tissue extraction during the LSH-procedure.48-50;52;92;93;98;109-130 This has become a 
controversial object of discussion. Mainly, there is a concern regarding the risk of 
complications caused by the morcellator.49;52;92;98;109;115;117;120;125;126 The possibility of 
these complications may have been underestimated, previously48. Firstly, there is a risk 
of intra-operative morcellator injury.52;92 In addition, there is risk of retained tissue 
after the procedure by using the morcellator.112;113;119;121;127;131 Finally, there is a risk of 
morcellating unanticipated uterine pathology including malignancy.48-50;92;93;98;109-
111;114;119;120;122-126;128;130;131 Fortunately, the complication-rate of using a morcellator is 
very low.52;109 Therefore, the morcellator has been regarded a safe device to use in 
experienced hands for selected women after a thoroughly preoperative 
evaluation.28;48;52;109  
According to the Norwegian Law for patient rights § 3.1: “The patient has the 
right to participate in choosing between available and medically sound methods of 
treatment.”132 Traditionally, the gynecologists are counseling women in choosing the 
appropriate method of approach and whether to preserve the cervix or not. Due to the 
low incidence of complications and the benefits of tissue extraction by morcellation, 
there is no strict routine in Norway to thoroughly inform patients of the use of 
morcellator or other medical devices during surgery. The gynecologist chooses the 
best equipment for the procedure. In contrast, complications caused by a morcellator 
are often severe and associated with high morbidity and increased 
mortality.98;105;109;122;125 Consequently, the U.S. Food and Drug Administration (FDA) 
issued April 17th 2014 a safety communication where they discourage the use of 
laparoscopic power morcellator for fibroids during hysterectomy.49 If a morcellator 
should be used during hysterectomy, the FDA instructs all health care providers in the 
US to inform patients that fibroids may contain unexpected cancerous tissue and that 
the morcellator may spread the cancer and significantly worsening their prognosis. In 
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addition, the FDA recommended a thorough discussion of benefits and risk of all 
treatments with the patients. Both, the American College of Obstetricians and 
Gynecologists and AAGL Advancing Minimally Invasive Gynecology Worldwide 
have issued thorough special reports on this topic following the FDA safety 
communication for the use of power morcellator.48;50 The European Society for 
Gynaecological Endoscopy (ESGE) is also preparing a review paper on morcellation 
of fibroids.93 Furthermore, gynaecologists worldwide are currently working to improve 
the LSH procedure and medical devices are developed to conduct a safe tissue 
extraction during LSH and myomectomy.129;133;134 
 The literature of outcomes following MIS hysterectomies mainly consists of 
case series and retrospective reports.5;22;28;29;35 Therefore, there is a lack of prospective 
trials including women with pelvic pain, endometriosis and adenomyosis comparing 
outcomes after different methods of hysterectomy. Consequently, there is a need for 
RCTs to compare long-term clinical outcomes after these procedures.4;22;28;35 The 
persistent controversies regarding methods of MIS hysterectomies encouraged us to 
carry out the trials included in this PhD thesis. The main objectives of surgical 
treatment in patients with benign conditions are through a safe method to eradicate or 
reduce symptoms and by this to improve the quality of life (Qol). For this reason, it is 
vital to evaluate patient satisfaction and Qol when outcomes of hysterectomy in 
women with benign gynecological conditions are studied. The objectives of the trials 
in this PhD thesis were to explore pelvic pain, patient satisfaction and Qol after LSH 
and TLH, respectively.  
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6. AIMS OF THE THESIS 
 
The aim of this current thesis was to compare clinical outcomes after different 
LH techniques. Our first focus was to explore the cervical stump symptoms (vaginal 
bleeding and cyclic pelvic pain) and patient satisfaction after LSH. In addition, we 
wanted to compare such clinical outcomes after LSH and TLH, respectively. 
Furthermore, we wanted to explore outcomes of cyclic pelvic pain, patient satisfaction 
and Qol in women with or without endometriosis and adenomyosis.  
 
Specifically, the aims were:  
 
1. To compare the occurrence of vaginal bleeding and patient satisfaction 12 months 
after LSH performed with and without excision of the endocervix in a reverse cone 
pattern (Paper 1). 
2. To evaluate the occurrence, intensity and reduction of cyclic pelvic pain and 
patient satisfaction 12 months after LSH (Paper 2). 
3. To compare the occurrence, intensity and reduction of cyclic pelvic pain 12 months 
after TLH and LSH, respectively (Paper 3).  
4. To compare patient satisfaction and quality of life 12 months after TLH and LSH, 
respectively (Paper 3).  
5. To compare cyclic pelvic pain and patient satisfaction 12 months after TLH and 
LSH in women with or without perioperative detection of endometriosis and in 
women with or without histological confirmed adenomyosis (Paper 2 and 3).   
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7. MATERIALS AND METHODS 
 
 7.1 Approvals  
The studies included in this PhD thesis were conducted in accordance with the 
Declaration of Helsinki and national as well as local regulations. The Regional 
Committee for Medical Research Ethics in eastern and southern Norway, the Scientific 
Advisory Board and the Advisory Committee on the Protection of Patient Records at 
Oslo University Hospital (OUS) approved the trial protocols before recruiting study 
participants. Written informed consent was obtained from all study participants. The 
studies were registered in ClinicalTrials.gov, clinical trial-identifier NCT00921778 
and NCT01289314.135  
 
7.2 Design 
All studies included in this PhD thesis were performed as single-center trials in 
a gynecological department of a Norwegian university teaching hospital. We 
conducted two blinded RCTs. These trials were carried out and reported according to 
the CONSORT guidelines.136;137 Each of  the RCTs got a short title. The first RCT was 
named the Lapcone-trial (Paper 1). The second RCT was entitled the Lap-Hyst-trial 
(Paper 3). In addition, an open prospective observational trial was performed (Paper 
2).  
 
7.3 Patient selection 
7.3.1 Enrollment and study populations 
Premenopausal women referred to OUS for hysterectomy on the basis of a 
benign condition were eligible for study recruitment. The women were invited to 
participate and enrolled in the trials at the outpatient clinic. The authors of the studies 
were primarily responsible for recruiting women.  
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7.3.2 Inclusion / exclusion criteria 
Exclusion criteria for all three trials were women unable to communicate in 
Norwegian language, previous history of cervical dysplasia, cellular changes 
suggestive of cervical dysplasia or malignancy in preoperative cervical smear or 
atypical hyperplasia or malignancy in preoperative endometrial biopsy. Furthermore, 
women with a coexisting condition requiring removal of remaining ovaries, 
postmenopausal women and women using hormone therapy were not included.  
In addition, women who after clinical evaluation were found to benefit from 
vaginal, abdominal or total laparoscopic hysterectomy were not invited to participate 
in the trials. This exclusion criteria was more specified in the Lap-Hyst-trial. Women 
with pelvic organ prolapse (POP) more than grade 1 and preoperative signs of severe 
or deep infiltrating endometriosis or with preoperative symptoms dominated by a non-
cyclic chronically pelvic pain were not invited to participate in this trial (Paper 3).138-
140 Consequently, peritoneal endometriosis or endometriosis in the pouch of Douglas 
was not a contraindication of being included in the trials, unless leaving the cervix 
compromised the removal or destruction of endometriosis. The preoperative 
classification of severe endometriosis was defined as presence of large 
endometriomas, suspected extensive adhesions or kissing ovaries due to 
endometriosis.139;140  
A supplementary criterion of exclusion regarding the uterine size was added in 
Paper 3. Women with a substantially enlarged uterus were not included in the trial. 
This was defined as measurements by transvaginal ultrasound of the corpus uteri more 
than 10 or 12 centimeters in anterior-posterior or transversal diameter, respectively.  
A fundamental criterion of inclusion in both Paper 2 and 3 was the occurrence 
of preoperative cyclic pelvic pain. This was defined as premenstrual pain or 
dysmenorrhea. The study participants in Paper 2 were recruited among women 
participating in the Lapcone-trial (Paper 1). Women with no preoperative cyclic pelvic 
pain and study participants treated with other methods of hysterectomy including all 
conversions to laparotomy were not included in Paper 3. Therefore, this observational 
trial is a per protocol analysis of women included in Paper 1 with preoperative cyclic 
pelvic pain treated by LSH. 
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7.4 Description of interventional procedures 
The study participants underwent laparoscopic hysterectomy in general 
anesthesia. The Pelosi Mobilizer by Apple Medical Corporation, Marlboro, MA, 
United States and Vcare® uterine manipulator by ConMed Endosurgery, Utica, NY, 
United States, were used during LSH and TLH, respectively. 
In the Lapcone-trial, the study participants were either allocated to the 
standardized operative technique of LSH at our department or LSH performed with 
excision of the endocervix in a reverse cone pattern.31;51;86 Both methods included 
electrocoagulation of the upper cervical canal. The excision of the endocervix was 
performed by a CE-approved monopolar LEEP-device by Ross Electro Medical Ltd, 
London, UK.86 This device was entitled the Lapcone electrode and designed for use 
during laparoscopy, Figures 1a,1b and 2.  
 
Figure 1a and 1b: Pictures of the Lapcone electrode. Lenght: 25cm, 6x10, Art. No. 
REM-270. The device is made by Ross Electro Medical Ltd, London, UK. 
 
1a) 
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1b) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: An illustration of conducting the excision of the endocervix by using the 
monopolar the Lapcone electrode, used for reverse loop electrosurgical excision 
procedure during laparoscopy. The illustration is made by and printed with permission 
from Heidi Øvergaard. 
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In the Lap-Hyst-trial, the study participants were randomised to either TLH or 
LSH. In this RCT, the LSH was performed with the standardized operative technique 
without excision of the endocervix.31;51 During TLH, the surgeons individually 
determined the method and suture for vaginal cuff closure. This was either performed 
by a continuous suture of 0 (3.5 Metric) V-locTM 180 absorbable polyglyconated or 
cross-sutures of 0-Polysorb, manufactured by Covidien, Dublin, Ireland. Both 
consultants and residents performed the LSH-procedures in the Lapcone-trial. In the 
Lap-Hyst-trial, six predefined endoscopic consultants performed the procedures.  All 
study participants in the Lap-Hyst-trial received 1500-milligram of metronidazole and 
400-milligram doxycycline intravenously during the procedure as a single dose of 
prophylactic antibiotics (Paper 3). The study participants in the Lapcone-trial did not 
receive prophylactic antibiotics (Paper 1 and 2). Endometriosis diagnosed 
perioperatively was treated during the procedure by electrocoagulation or excision.  
 
7.5 Collection of data and outcome measures 
The study participants and the primary study examiner registered most of the 
outcome measures at the outpatient clinic preoperatively and at follow-up 12 months 
after surgery. A written standardized questionnaire was used. Some outcome measures 
were reported through a standardized clinical interview and examination completed by 
the primary examiner. In addition in the Lap-Hyst-trial, the validated and well-
documented Short Form 36 (SF-36) was used to evaluate Qol (Paper 3).141  
Preoperative variables included age, body mass index (BMI), number of 
previous births and caesarean sections, indication for hysterectomy, any previous 
pelvic or abdominal surgery, medication, use of Levonorgestrel-releasing intrauterine 
system, other medical conditions and uterine size measured by transvaginal ultrasound 
(anterior-posterior diameter and width of corpus uteri). 
The amount and type of vaginal bleeding (cyclic, irregular or contact bleeding) 
were registered both preoperatively and 12 months after surgery. This was reported in 
a four-graded ordinal scale (no bleeding, weak bleeding, normal bleeding or heavy 
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bleeding) and using a visual analogue scale (VAS), range 0-10. The occurrence and 
intensity of cyclic pelvic pain were registered in a four-graded ordinal scale (no pain, 
mild pain, moderate pain or severe pain) and a VAS (range 0-10). After hysterectomy, 
the cyclic pelvic pain was defined as cyclic pelvic pain with or without concomitant 
vaginal bleeding. The occurrence of non-cyclic chronic pelvic pain was also 
registered.  In addition, occurrence and type of urine incontinence and occurrence of 
hot flashes were registered both preoperatively and 12 months after surgery. To 
explore potential menopause, the serum levels of Oestradiol, Follicle Stimulating 
Hormone, Lutein hormone were analyzed preoperatively and 12 months after 
hysterectomy. Additional analyzes of anti-Mullerian hormone were performed in The 
Lap-Hyst-trial. The patient satisfaction was reported 12 months after the procedures in 
an ordinal scale and a VAS (range 0-10). The length of the remaining cervix 12 
months after LSH was measured by transvaginal ultrasound. In the Lap-Hyst-trial, the 
occurrence and type of pelvic organ prolapse (POP) defined by Pelvic Organ Prolapse-
Quantification (POP-Q) was registered both preoperatively and 12 months after 
surgery.138 Additional variables 12 months after hysterectomy were return to normal 
activity (days) and any new symptoms.  
A scrub-nurse recorded the perioperative variables (operation time, weight of 
specimen, perioperative complications and estimated blood loss).  The nurses at the 
gynecological ward registered body temperature, length of stay and complications 
before discharge from the hospital. All further contacts (re-consultations and 
readmissions) and complications during the 12-month follow-up were continuously 
reported to the primary investigator.  
In all trials, preoperative cervical cytology and endometrial biopsy, histological 
analysis of specimen from the surgical procedure and cervical cytology 12 months 
after surgery were registered. A dedicated pathologist analyzed all specimens with a 
2.0 millimeters dept of invasion of endometrial glands below the basalis layer as 
diagnostic cutoff criteria for adenomyosis.  
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7.6 Randomisation and concealed allocated treatment 
In the two RCTs, a full randomisation at a ratio of 1:1 was performed using the 
randomisation plan generator with permuted blocks.142 A study nurse, not otherwise 
involved in the study, performed the randomisation procedure. The treatment 
assignment was concealed in numbered envelopes stored in the operating theatre. The 
study nurse and a senior supervisor of the trials kept a code list with the concealed 
allocated treatments throughout the follow-up period 12 months after the procedures. 
In the Lapcone-trial, the allocated treatment was revealed for the surgeon after 
amputation of the cervix, and the assigned intervention performed. The surgeon 
documented the following description in the medical record: “The LSH was performed 
according to the allocated treatment in the Lapcone-trial”. Consequently, the allocated 
treatment was blinded both for the study participants and for the primary examiner at 
follow-up consultations. The primary examiner got access to the code list after all 
outcome variables were registered in an internal research database. The study 
participants were informed of the allocated treatment after the follow-up consultation 
12 months after LSH.  
In the Lap-Hyst-trial, the envelope was not opened until general anaesthesia of 
the study participant was established. To ensure good medical care, a description of 
the allocated treatment (TLH or LSH) was registered in the medical chart. In order to 
increase the validity of the trial, the assigned procedure was kept blinded for the study 
participants throughout the follow-up period. In the Lap-Hyst trial, the primary 
examiner and study participants were informed of allocated treatment after completing 
the study forms at follow up 12 months after hysterectomy.  
 
7.7 Statistics  
 
7.7.1 Test power  
 Power analyses were conducted before commencing the RCTs. The test power 
and level of significance in both trials were set to 90 % and 0.05, respectively. 
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In the Lapcone-trial, there was an expected occurrence of vaginal bleeding in 24 
% after LSH for women treated by the standard procedure.31 A reduction in occurrence 
of vaginal bleeding from 24 % to 5 % was considered clinically significant. The 
number of women required was calculated to be 140. 
For participating women in The Lap-Hyst-trial, the expected mean of cyclic 
pelvic pain reduction treated by LSH was 3.3 with a standard deviation (SD) of 2.7.31 
During planning of the trial, there was no available data for the expected reduction of 
pain after TLH. A difference in pelvic pain reduction between LSH and TLH equal to 
1 SD was considered to be of clinical importance. Consequently, 62 women were 
required in the trial. 
 
7.7.2 Statistical analysis  
In the two RCTs, data were analyzed according to the principle of intention to 
treat. An additional analysis per protocol was performed if there were any deviations 
in the treatment or follow-up. The prospective observational study was an open trial of 
women treated by LSH. Therefore, this trial was analyzed per protocol.  
All statistical tests were two-sided and p= 0.05 was considered statistical 
significant. The statistical analyses were performed using commercial available 
software (SPSS version 15.0 and 18.0, SPSS, Inc., Chicago, IL). Normally distributed 
continuous data from two study groups were analyzed using a two-sided Independent 
Samples Student t-test and the Paired Samples t-test when paired. For non-normally 
distributed data, the Mann-Whitney U test and Wilcoxon Signed Rank Test were used. 
Categorical data were analyzed using Pearson Chi-Square. 
 
7.8 Ethics 
Before recruiting study participants, The Regional Committee for Medical 
Research Ethics in eastern and southern Norway approved trial protocols. A pilot-
study had been performed during planning of the first RCT. This validated the 
Lapcone electrode as a safe and quick method for removal of the endocervix in a 
reverse cone during LSH.86 Therefore, the trial protocol for the Lapcone-trial was 
approved without major annotations (Paper 1 and 2). 
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In contrast, there were some necessary ethical considerations regarding 
conducting of the Lap-Hyst-trial (Paper 3). This was mainly related to the concealment 
of the allocated treatment throughout the follow-up period of 12 months after the 
procedures. According to the study protocol, the study participants should not be 
informed whether cervix was preserved or not during hysterectomy during the follow 
up periode. According to the Norwegian Law for patient rights (Norwegian: Lov om 
pasient- og brukerrettigheter) § 3.2 The patient`s right to information “The patient 
shall have the information that is necessary to obtain an insight to his or her health 
condition and the content of health care”.132 To achieve this and the appropriate ethical 
approval of the study design, the following statement was included in the information 
(in Norwegian) given to women eligible for study recruitment when they were invited 
to participate and enrolled in the trial: “If complications related to the allocated 
treatment occur, study participants will obtain information regarding allocated 
treatment. If study participants for other reasons wish to obtain information of 
allocated treatment performed, she has the right to access her medical records to get 
such information, according to Law for patient rights §3-2.”  
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8. SUMMARY OF RESULTS 
 
8.1 Laparoscopic Supracervical Hysterectomy Performed With and 
Without Excision of the Endocervix: A Randomized Controlled Trial. 
(Paper 1) 
A total of 140 women were randomised to standard laparoscopic supracervical 
hysterectomy (n = 70) or laparoscopic supracervical hysterectomy with excision of the 
endocervix in a reverse cone pattern (n = 70). They were followed up according to the 
study protocol (Figure 3). There were no differences between the two allocated 
treatment groups in preoperative demographic data and perioperative variables. We 
found no difference in occurrence of vaginal bleeding or patient satisfaction 12 months 
after the procedures (table 3). For all study participants, the mean amount of vaginal 
bleeding was reduced from 7.4 (SD 2.4) preoperatively to 0.2 (SD 0.4) 12 months after 
LSH measured by VAS (p<0.01). The mean patient satisfaction was 9.0 (SD 1.9) 
measured by VAS in women with bleeding 12 months after LSH compared to 9.4 (SD 
1.2) for women without bleeding after surgery, p= 0.15. Among women treated by 
excision of the endocervix (n=59), endometrial tissue was detected in seven (12.7%) 
specimens of the removed cones. The mean length of the remaining cervix measured 
by transvaginal ultrasound was 2.7 cm (SD 0.6). The length of the cervix did neither 
affect the occurrence of endometrial tissue in the endocervical-cones nor vaginal 
bleeding after LSH. 
 
Table 3. Outcomes of vaginal bleeding and patient satisfaction 12 months after 
Laparoscopic supracervical hysterectomy in both treatment groups. (Paper I) 
Outcomes 12 months after LSH1 
LSH performed 
without excision of the 
endocervix (n=67)1 
LSH performed with 
excision of the 
endocervix  (n=63)1 
 
p-
value 
No bleeding episodes, n (%) 45 (67.2) 42 (66.7) 0.95 
Regular bleeding,n (%) 11 (16.4) 11 (18.0) 0.99 
Irregular bleeding episodes, n (%) 11 (16.4) 10 (15.9) 0.99 
Amount of bleeding, (VAS), mean (SD)2 0.2 (0.4) 0.3 (0.5) 0.35 
Patient satisfaction (VAS), mean (SD)2 9.3 (1.4) 9.2 (1.5) 0.73 
1 Laparoscopic supracervical hysterectomy (LSH) 
2  Visual analogue scale (VAS), range 0-10 
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Figure 3: Study flow chart Paper 1. 
 
 
 
 
 
  
 
 
Assessed for eligibility (n=173) 
Excluded (n=33) 
- Not meeting inclusion criteria (n=3) 
- Refused to participate (n= 30) 
 
 
Lost to follow-up (n=7) 
 
 
Analyzed (n=63) 
 
 
Analyzed (n=67) 
 
 
Laparoscopic supracervical 
hysterectomy performed with excision 
of the endocervix (n = 70) 
 
-Received allocated intervention (n=57) 
-Did not receive allocated intervention (n=13) 
 
 
  
 
Laparoscopic supracervical 
hysterectomy performed without 
excision of the endocervix (n = 70) 
 
-Received allocated intervention (n= 62) 
-Did not receive allocated intervention (n=8) 
Enrollment 
 
Lost to follow-up (n=3) 
 
 
Included in the study and randomized (n = 140) 
Allocation 
Analysis 
Follow-Up 
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8.2 Pelvic Pain and Patient Satisfaction after Laparoscopic Supracervical 
Hysterectomy, Prospective Trial. (Paper 2) 
A total of 113 women with preoperative cyclic pelvic pain and treated by LSH 
were included in the trial. Eight women (7.1%) were lost to follow up. Endometriosis 
was detected perioperatively in 14 (% ) study participants. After LSH, adenomyosis 
was found in 19 (18.1%) of the specimens.  
The occurrence of cyclic pelvic pain was reduced to a minimum 12 months 
after the procedure, p < .01 (table 4). The mean intensity of cyclic pelvic pain was 
reduced from 5.5 (SD 2.4) preoperatively to 0.7 (SD 1.5) measured by VAS 12 months 
after LSH, p < 0.01. There was no difference in mean reduction of cyclic pelvic pain 
among women with adenomyosis compared with women without adenomyosis 
measured by VAS, p= 0.45. The mean patient satisfaction for women with and without 
adenomyosis was 9.5 (SD 1.3) and 9.2 (SD 1.5) measured by VAS, respectively (p= 
0.24). Women with endometriosis reported a higher intensity of cyclic pelvic pain 
preoperatively compared to women with no signs of endometriosis during LSH, 
p=0.05.  There was no difference in reduction of cyclic pelvic pain 12 months after the 
procedure in women with or without a perioperative detection of endometriosis, 
p=0.60. The mean patient satisfaction measured by VAS 12 months after LSH for 
women with or without perioperative detection of endometriosis was 9.3 (SD 1.5) and 
9.3 (SD 1.7), respectively (p= 0.9). The length of the remaining cervix after LSH 
(mean 2.7 cm, SD 0.6) did not appear to influence the occurrence or intensity of pelvic 
pain 12 months after the procedure.  
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Table 4:  Cyclic pelvic pain among study participants in the trial with complete follow-
up by an ordinal and visual analogue scale. The scores are reported preoperatively and 
12 months after laparoscopic supracervical hysterectomy. The table is for subgroups of 
women with and without adenomyosis and endometriosis, respectively. (Paper II) 
 
8.3 Pain reduction after total laparoscopic hysterectomy and laparoscopic 
supracervical hysterectomy among women with dysmenorrhea: a 
randomised controlled trial. (Paper 3) 
In total, 62 women were included in the trial. They were followed-up according 
to the study flow chart, figure 4. The preoperative demographic variables and intensity 
of cyclic pelvic pain were comparable for the two allocated treatment groups. The 
mean duration of surgery in the LSH-group was 76.0 (SD 25.1) minutes compared to 
102.7 (SD 27.3) for TLH, p=0.01.  
Cyclic pelvic pain 
Adenomyosis2 Endometriosis3 
Adenomyosis 
detected 
(n = 19) 
No 
Adenomyosis 
( n = 86) 
Endometriosis 
detected 
 (n = 14) 
No 
Endometriosis 
(n = 91) 
Pr
eo
pe
ra
tiv
el
y Weak pelvic pain, n (%) 4 (21.1) 28 (32.6) 0 (0.0) 32 (35.2) 
Moderate pelvic pain, n (%) 7 (36.8) 39 (45.3) 9 (64.3) 37 (40.7) 
Severe pelvic pain, n (%) 8 (42.1) 19 ( 22.1)  5 (35.7) 22 (24.2) 
Pelvic pain, mean VAS (SD)4 6.3 (2.7) 5.4 (2.3) 6.4 (1.8) 5.3 (2.6) 
12
 m
on
th
s a
fte
r 
L
SH
1 No pelvic pain, n (%) 12 (63.2) 59 (68.6) 10 (71.4) 62 (68.1) 
Weak pelvic pain, n (%) 4 (21.1) 23 (26.7) 2 (14.3) 24 (26.4) 
Moderate pelvic pain, n (%) 2 (10.5) 4 (4.7) 1 (7.1) 5 (5.5) 
Severe pelvic pain, n (%) 1  (5.3) 0 (0.0) 1 (7.1) 0 (0.0) 
Pelvic pain, mean VAS (SD)4 1.0 (2.0) 0.6 (1.4) 1.2 (2.6) 0.6 (1.3) 
1 Laparoscopic supracervical hysterectomy (LSH).  
2 Adenomyosis detected in specimen from operation.  
3 Endometriosis detected perioperatively.  
4 Visual analogue scale (VAS), range 0-10. 
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Figure 4: Study flow chart Paper 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessed for eligibility  
(n=187) 
Excluded (n=125) 
- Not meeting inclusion criteria (n=72) 
- Refused to participate (n= 53) 
 
 
Lost to follow-up (n=0) 
 
 
Analyzed (n=31) 
 
 
Analyzed (n=28) 
 
Allocated to  
Total laparoscopic 
hysterectomy  (n = 31) 
 
-Received allocated intervention (n=31) 
-Did not receive allocated intervention (n=0) 
 
 
  
Allocated to  
Laparoscopic supracervical 
hysterectomy (n = 31) 
 
 
-Received allocated intervention (n= 30) 
-Did not receive allocated intervention (n=1) 
 -Not operated due to other medical  contitions 
Enrollment 
 
Lost to follow-up (n=3) 
-Did not meet at follow-up consultation  
 
Included in the study and randomised  
(N = 62) 
Allocation 
Analysis 
Follow-Up  
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Table 5: Outcome measures in the allocated treatment groups 12 months after 
hysterectomy. (Paper 3) 
 
TLH1 
(n=31) 
LSH2 
(n=28) 
 
p-value 
Cyclic pelvic pain reduction (VAS), 
mean (SD)3,4 
5.8 (2.6) 6.0 (2.6) 0.77 
Cyclic pelvic pain 12 months 
after hysterectomy (VAS), mean (SD)3 
0.8 (1.6) 0.8 (2.0) 0.94 
Cyclic pelvic pain 12 months 
after hysterectomy, n (%) 
10 (32.3) 7 (25.0) 0.54 
Patient satisfaction 12 months 
after hysterectomy, mean VAS (SD)3 
9.3 (1.5) 9.1 (1.2) 0.43 
Qol 12 months after hysterectomy 
(SF-36, total score), mean (SD)5 
81.6 (17.8) 80.2 (18.0) 0.69 
Qol (SF-36, total score) improvement, 
mean (SD)5,6 
17.6 (20.0) 13.9 (26.0) 0.56 
Pelvic organ prolapse 12 months 
after hysterectomy, n (%)7 
10 (32.3) 5 (17.8) 0.23 
Occurrence of vaginal bleeding 
12 months after hysterectomy, n (%)8 
3 (9.7) 9 (32.1) 0.03 
1 Total laparoscopic hysterectomy (TLH).  
2 Laparoscopic supracervical hysterectomy (LSH).  
3 Visual analogue scale (VAS) Range 0-10.  
4 Cyclic pelvic pain reduction: The VAS preoperatively minus VAS 12 months after surgery.  
5 Quality of life (Qol) by Short form 36 (SF-36) Range 0-100. A total score is reported if  
   all questions of SF-36 are completed.   
6 Qol improvement: SF-36-score 12 months after surgery minus SF-36-score preoperatively.  
7 Pelvic organ prolapse (POP) 12 months after hysterectomy by POP-Quantification, all grade 1.  
8 All bleeding episodes were minor, both cyclic and irregular bleeding reported. Irregular  
   bleeding episodes reported in the allocated treatment groups: TLH (n=3) and LSH (n=5).  
 
The mean reduction of cyclic pelvic pain 12 months after TLH and LSH 
measured by VAS 0-10 was 5.8 (SD 2.6) and 6.0 (2.6), respectively (p= 0.77) (table 
5). There were no differences between the two allocated treatment groups in 
occurrence and intensity of cyclic pelvic pain, patient satisfaction or Qol 12 months 
after hysterectomy, (p=0.54, p=0.94, p=0.43, p=0.69) respectively. The 
patientsatisfaction measured by VAS after TLH and LSH was 9.3 (SD 1.5) and 9.1 
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(SD 1.2), respectively. The mean Qol scores 12 months after hysterectomy measured 
by SF-36 were higher for all study participants and for both allocated treatment groups 
separately compared to the preoperative values, (p<0.02) respectively. 
Women with endometriosis (n=15) reported the same intensity of preoperative 
cyclic pelvic pain compared to women without endometriosis (n=46), p= 0.89 (table 
6). The reduction of cyclic pelvic pain 12 months after hysterectomy measured by 
VAS for women with and without endometriosis was 5.8 (SD 2.2) and 5.9 (SD 2.6), 
respectively. In contrast, study participants with adenomyosis (n=27) reported higher 
preoperative cyclic pelvic pain (mean 7.7, SD 1.6) compared to women without this 
diagnosis (n=34) (mean 6.0, SD 2.4), p=0.03. Furthermore, there was a tendency of a 
greater pelvic pain reduction in women with adenomyosis (mean 6.5, SD 2.3) 
compared to women without this diagnosis (mean 5.3, SD 2.6), p=0.06. There was no 
significant difference in intensity of cyclic pelvic pain in women with or without 
adenomyosis 12 months after hysterectomy, p=0.23. The mean patient satisfaction 12 
months after hysterectomy for women with or without endometriosis was 9.2 (SD 0.6) 
and 9.2 (SD 1.5), respectively (p=0.99). The corresponding figures for women with or 
without adenomyosis were 9.1 (SD 1.7) and 9.3 (SD 0.9), respectively (p=0.55). There 
were similar improvements in Qol scores for women with endometriosis and 
adenomyosis compared to women without these conditions, p>0.1.  
The women returned to normal activity after LSH and TLH within mean 25.8 
(SD 11.9) and 35.8 (SD 26.8) days, respectively (p=0.15). There was a trend towards 
more re-consultations after discharge from the hospital in the TLH-group (n=11), 
compared to the women who were treated with LSH (n=5), p=0.08. As expected, we 
found a higher occurrence of vaginal bleeding after LSH compared to TLH, p=0.05. 
The occurrence of vaginal bleeding did neither affect patient satisfaction nor Qol 12 
months after hysterectomy.  
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Table 6: Outcome measures 12 months after hysterectomy in the allocated treatment 
groups for women with and without endometriosis or adenomyosis, respectively. 
(Paper 3) 
   
TLH1 
(n=31) 
LSH2 
(n=30) 
p-
value 
E
N
D
O
M
E
TR
IO
S
 
No endometriosis detected during surgery, n (%) 
Reduction of cyclic pelvic pain (VAS), mean (SD) 3,4 
Cyclic pelvic pain (VAS) 12 months after hysterectomy, mean (SD) 3 
Patient satisfaction (VAS) 12 months after hysterectomy, mean (SD) 3 
Qol (SF-36, total score) 12 months after hysterectomy, mean (SD)5 
24 (77.4) 
5.8 (2.6) 
0.8 (1.6) 
9.3 (1.6) 
83.2 (17.2) 
22 (73.3) 
5.9 (2.7) 
0.8 (2.3) 
9.2 (1.4) 
82.1 (17.3) 
0.71 
0.89 
0.98 
0.86 
0.82 
Endometriosis detected and treated during surgery, n (%) 
Reduction of cyclic pelvic pain (VAS), mean (SD) 3,4 
Cyclic pelvic pain (VAS) 12 months after hysterectomy, mean (SD) 3 
Patient satisfaction (VAS) 12 months after hysterectomy, mean (SD) 3 
Qol (SF-36, total score) 12 months after hysterectomy, mean (SD)5 
7 (22.6) 
5.6 (2.8) 
1.0 (1.5) 
9.4 (0.5) 
78.8 (20.5) 
8 (26.7) 
6.1 (1.5) 
0.8 (1.4) 
9.0 (0.7) 
74.0 (20.2) 
0.71 
0.71 
0.82 
0.26 
0.68 
A
D
E
N
O
M
Y
O
SI
S No adenomyosis in specimen from hysterectomy, n (%) 
Reduction of cyclic pelvic pain (VAS), mean (SD) 3,4 
Cyclic pelvic pain (VAS) 12 months after hysterectomy, mean (SD) 3 
Patient satisfaction (VAS) 12 months after hysterectomy, mean (SD) 3 
Qol (SF-36, total score) 12 months after hysterectomy, mean (SD)5 
16 (51.6) 
4.9 (2.6) 
0.5 (1.2) 
9.5 (0.6) 
83.6 (16.0) 
18 (60.0) 
5.7 (2.6) 
0.6 (2.1) 
9.1 (1.1) 
78.6 (17.1) 
0.51 
0.44 
0.93 
0.22 
0.41 
Adenomyosis detected in specimen from hysterectomy, n (%) 
Reduction of cyclic pelvic pain (VAS), mean (SD) 3,4 
Cyclic pelvic pain (VAS) 12 months after hysterectomy, mean (SD) 3 
Patient satisfaction (VAS) 12 months after hysterectomy, mean (SD)3 
Qol (SF-36, total score) 12 months after hysterectomy, mean (SD)5 
15 (48.4) 
6.6 (2.4) 
1.2 (1.8) 
9.1 (2.0) 
80.6 (20.0) 
12 (40.0) 
6.4 (2.2) 
1.1 (2.1) 
9.2 (1.4) 
82.4 (19.6) 
0.51 
0.74 
0.94 
0.88 
0.82 
1 Total laparoscopic hysterectomy (TLH).  
2 Laparoscopic supracervical hysterectomy (LSH). 
3 Visual analogue scale (VAS), Range 0-10.  
4 Cyclic pelvic pain reduction: preoperative VAS-score minus VAS-score  
  12 months after surgery.  
5 Quality of life (Qol) by Short form 36 (SF-36), Range 0-100.  
  A total score is reported if all questions of  SF-36 are completed.  
 
 
8.4  A comparison of the trials in the PhD thesis 
 In general, the preoperative demographic data and symptoms of study 
participants in the Lapcone-trial and the Lap-Hyst-trial were comparable, table 7. The 
study participants in the Lapcone-trial were included and procedures were performed 
in the period 09/2008 – 09/2010. The Lap-Hyst-trial was conducted in the period 
02/2011 – 11/2012 and followed up for 12 months after the procedures. 
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There were no differences in the main indications for hysterectomy between the 
two RCTs. The preoperative size of uterus and weight of specimen removed during 
hysterectomy were higher in the Lapcone-trial compared to the Lap-Hyst-trial, p<0.05.  
The mean duration of surgery in the Lapcone-trial was 98.5 (SD 35.6) minutes 
compared to 89.5 (SD 29.3) minutes in the Lap-Hyst-trial, p=0.07. If only the LSH 
procedures in the two trials were calculated, the mean time of operation in the 
Lapcone-trial (n=124) was 96.5 (SD 35.5) compared to 76.0 (SD 25.2) in the Lapcone 
trial (n=30), p=0.01. There was a higher incidence of endometriosis detected during 
surgery and adenomyosis identified in the specimen after hysterectomy in the Lap-
Hyst-trial compared to women participating the Lapcone-trial, respectively (p<0.05).  
Finally, there was a higher incidence of complications in the Lapcone-trial 
compared to the Lap-Hyst-trial, p<0.05. Mainly, minor complications occured. 
Converson to laparotomy (n=3) was registered as a minor complication in the 
Lapcone-trial. Among all women in this Ph.d thesis, five major complications 
occurred. One women who underwent LSH with excision of severe endometriosis 
detected perioperatively in the Lapcone-trial had an intra abdominal hematoma 
requiring surgical drainage 12 days after the procedure. The second major 
complication in this trial was an injury of the urine bladder in a woman with two 
previous caesarean sections. The injury was detected within 24 hours after the LSH, 
and a re-operation with laparoscopic suturing of the urine bladder was performed. For 
one woman in the Lap-Hyst trial, an infected cervical top hematoma was diagnosed 
and successfully treated with antibiotics three weeks after LSH. Two women in this 
trial experienced vaginal dehiscence three and six months after TLH, respectively. 
They were both re-operated with laparoscopic suture of the vaginal cuff. 
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Table 7: A comparison between the Lapcone-trial and the Lap-Hyst-trial. The trial 
period, preoperative demographic data, indication for hysterectomy, preoperative 
symptoms and measures, perioperative variables, histological diagnosis and 
complications in both trials.  
 
Variables 
The 
 Lapcone-trial 
(n=140) 
The  
Lap-Hyst-trial  
(n=62) 
p-
value 
 
Trial period of inclusion and hysterectomy 09/2008 - 
- 09/2010 
02/2011 - 
- 11/2012 
- 
Preoperative demographic data 
Age (years), mean (SD) 
Body mass index, mean (SD) 
44.2 (4.8) 
25.2 (4.9) 
44.8 (4.9) 
26.2 (5.6) 
0.62 
0.71 
Main indication for hysterectomy 
Fibroids, n (%) 
AUB, n (%) 
Dysmenorrea, n (%) 
 
73 (64.6) 
27 (23.9) 
13 (11.5) 
 
39 (62.9) 
14 (22.6) 
9 (14.5) 
 
- 
- 
- 
Preoperative symptoms and measures 
Vaginal bleeding (VAS), mean (SD)1 
Cyclic pelvic pain (VAS), mean (SD)1,2 
Uterine size transversal (cm), mean  (SD)3 
Uterine size AP (cm), mean (SD)3 
 
7.5 (2.3) 
5.5(2.6)2 
8.5 (9.5) 
7.8 (9.0) 
 
7.9 (1.8) 
6.7 (2.2) 
6.9 (1.3) 
5.8 (1.3) 
 
0.29 
0.01 
0.11 
0.04 
Perioperative variables and histological diagnosis 
Duration of surgery (minutes), mean (SD)4 
Weight of specimen (gram), mean (SD) 
Endometriosis detected during surgery, n (%)5 
Adenomyosis in specimen, n (%)6 
Histology sections examined in specimen, mean (SD)6 
Surgeons performed hysterectomy in the trial, n7 
 
98.5 (35.6) 
299.5 (271.3) 
12 (12.4) 
19 (16.7) 
5.5 (1.7) 
28 
 
89.5 (29.3) 
187.3 (93.7) 
15 (24.6) 
27 (44.3) 
5.8 (2.0) 
6 
 
0.07 
0.01 
0.04 
0.01 
0.87 
0.05 
Complications 
Total, peri- and postoperative complications, n (%) 
Minor complications, n (%) 
Major complications, n (%) 
 
25 (17.9) 
23 (16.4) 
2 (1.4) 
 
6 (9.8) 
3 (4.9) 
3 (4.9) 
 
0.05 
- 
- 
1 Measured by visual analogue scale (VAS), range 0-10. 2 There were 16 women without 
cyclic pelvic pain in the Lapcone-trial. The results reported in this table is the result of 
women in the observational trial, recruited among women with cyclic pelvic pain treated by 
LSH. 3 Measured by vaginal ultrasound, transversal and anterior-posterior (AP) diameter of 
the corpus uteri. 4 Time from application of the uterine manipulator until completed skin 
closure. 5 Endometriosis diagnosed during surgery was treated by electrocoagulation or 
excision. 6 Histological diagnosis of specimen from operation. Sub-group analysis of The 
Lap-Hyst-trial: adenomyosis was diagnosed in n=15 (48.4 %) and n=12 (44.0%) in the TLH 
and LSH-group, respectively (p=0.51)  7 Selected endoscopic consultants (n=6) performed 
all procedures in The Lap-Hyst-trial. Both consultants (n=12) and residents (n=16) 
performed the procedures in The Lapcone-trial. 
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9. DISCUSSION 
 
9.1 Patient selection 
 The study participants included in this PhD thesis were recruited among 
premenopausal women referred to the department of gynaecology OUS due to a 
benign condition requiring hysterectomy. Our department also offers a high amount of 
minimally invasive uterus-sparing treatment options. Hysteroscopic endometrial 
resection and hysteroscopic resection of fibroids (< 3.5 cm in diameter) are widely 
performed.143 Uterine artery embolization and myomectomy is also an option in 
selected cases.49;144-146 Thereby, other procedures are often recommended as 
alternatives to hysterectomy.143;144;146 Therefore in our department, the uterus is often 
significant enlarged when hysterectomy for a benign condition is performed. Our 
standard practice is to recommend VH as treatment of choice in women with a normal 
sized or slightly enlarged uterus (uterus size correspond to <9 weeks of pregnancy). If 
there is further enlargement of the uterus and for women with endometriosis, the 
laparoscopic approach is offered. Consequently, mainly women with an enlarged 
uterus due to fibroids were included in the trials.  
In Paper 3 there was a strict criterion of inclusion regarding the maximum size 
of the uterus. In contrast, there was no exclusion criterion in the size of uterus in Paper 
1 and 2. The diversity in criteria of inclusion may have caused the difference in 
outcomes such as preoperative size of uterus, weight of specimen and operating time 
in the two RCTs. Furthermore, at the time we planned and conducted study 1, our 
department had no predefined limits regarding the size of uterus when offering LSH as 
an option. There was an attitude to offer the laparoscopic approach to the highest 
degree of women referred to hysterectomy. Thereby, the feasibility and boundaries of 
the laparoscopic approach were tested out. If a perioperative risk of safety by 
conducting the LSH-procedure occurred, a conversion to laparotomy was carried out. 
This approach has probably influenced the incidence of conversion to laparotomy in 
Paper 1. In 2010, the criteria for LSH in our department were modified. We currently 
recommend abdominal hysterectomy for women with an enlargement of uterus that 
correspond to >15 weeks of pregnancy. Consequently, we offer MIS hysterectomy to 
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women when we are convinced this method is feasible without increasing the risk of 
intra-operative complications.  
 Study participants in the Lapcone trial were included among women referred 
and planned for LSH. The primary examiner of the trial did not overrule a 
recommendation for LSH given by a consultants in the department. A difference in 
preoperative evaluation among gynecologists might explain the heterogeneity of 
women included in the Lapcone-trial. In contrast, the first author recruited all the study 
participants in the Lap-Hyst-trial. In this trial, the inclusion/exclusion criteria were 
more strictly defined. The preoperative evaluation of symptoms and clinical findings 
of study participants in this trial were homogeneous compared to the study participants 
in the Lapcone-trial. Consequently, the population studied in Paper 3 was more 
selected. The study participants in Paper 1 represent a general population of women 
planned for LSH at the time this trial was conducted. 
  The RCTs conducted were designed with concealment of the allocated 
treatment during the follow-up of 12 months. This concealment was the major reason 
for refusal to participate in the Lap-Hyst-trial. Except for the excision of the 
endocervix, the allocated procedures offered in study 1 were to a large extent the same. 
The minor difference between the procedures in this trial may have caused fewer 
refusals to participate in this trial compared to the Lap-Hyst-trial.  
 
9.2 Methodological considerations 
 
9.2.1 Study design 
The design of the two RCTs ensured a strong external validity for the primary 
outcome of the trials. Especiallly, the blinding of the allocated treatment throughout 12 
months follow-up after the procedures improved the quality of these trials.  
 Some methodological weaknesses need to be acknowledged. The lack of 
reference group in Paper 2 weakens the conclusion of this prospective observational 
trial. In addition, the number of study participants is the main limitation of the trials 
included in this PhD thesis. Consequently, results of subgroup analyzes in the trials 
must be interpreted with caution. To estimate the number of women needed for the 
main outcome of the RCTs, power analyses were performed. The prevalence of 
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endometriosis and adenomyosis is reported in a wide range (20-60 %) in different 
studies of hysterectomy.131;147-150 If the trials should have been powered for sub-group 
analysis of endometriosis and adenomyosis, additional pilot studies and supplementary 
power analyses should have been performed. This would probably have concluded 
with requirement of a substantially larger study population in both of the trials if 
subgroup analyses with adequate power and level of significance for these conditions 
should have been conducted. It is both costly and time-consuming to conduct an even 
larger high-quality RCT comparing different methods of hysterectomies. This was not 
achievable within the granted recourses available for this PhD thesis.  
 
9.2.2 Outcome measures 
  Most outcome measures in all three trials were subjective. The use of a more 
accurate method for assessment of periodic blood loss, such as the alkaline hematin 
method, may have improved the quality of Paper 1.151 However, although this method 
is more reliable than a VAS, it requires that the study participants hand in all soiled 
sanitary pads and tampons to the study investigator. Consequently, we feared that this 
method would have made study recruitment difficult and follow-up more challenging. 
Clinical evaluations in response of treatment in benign conditions are usually based on 
subjective perception of symptoms. Therefore, the measurements used in our studies 
reflect the foundation most commonly used for clinical decisions.  
  The VAS was used to measure the severity of vaginal bleeding, patient 
satisfaction and cyclic pelvic pain in the trials. This scale is widely used in clinical 
practice for evaluation of treatment. The VAS is validated for use in gynecological 
conditions and for recall pain.152 This scale is a continuous variable and does not force 
study participants into fixed categories. Therefore, the scale can be used for parametric 
statistical analysis.  
 Both Paper 1 and 2 had profited on an additional variable evaluating the Qol. 
Therefore, this outcome was added during planning of Paper 3. In this trial, we used 
the SF-36.141 This is a well-documented Qol-scale. The Uterine Fibroid Symptom and 
Quality of Life questionnaire is more specific for gynecological symptoms.153 In 
contrast, there is no consensus of which validated Qol-scale that should be preferred 
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for trials evaluating outcomes following hysterectomy. In addition, the trials had most 
likely improved if we had explored outcome of endometriosis using a validated 
endometriosis-scale like the Endometriosis Fertility Index (EFI) or ENZIAN 
score.139;140;154 Unfortunately, these scales were not systematically used in clinical 
practice in our department at the time we conducted the trial. The EFI and EZIAN 
score are used to evaluate the peri-operative severity of endometriosis. The definition 
of severe endometriosis used in our trials ensured the preoperative detection of severe 
endometriosis by a clinical examination and vaginal ultrasound, preoperatively. 
Therefore, the scales were not necessary for correct inclusion in the trials. 
 Furthermore, to make a correct diagnosis of  adenomyosis in the specimen after 
morcellation is debatable.115;118 Adenomyosis is defined as intramyometrial presence 
of endometrial mucosa surrounded by reactive hypertrophic myometrium.150 The 
morcellation of the uterus during LSH may be an impediment for a correct histological 
diagnosis. In addition, a strict definition of adenomyosis regarding dept of invasion 
criteria for endometrial glands within the myometrium may also cause a low 
prevalence in our trials.115;118;147;149;150;155 
 A written standardized questionnaire was used for all three trials. Except for the 
SF-36 questionnaire, the primary examiner was not blinded for the written answers 
given by the study participants. This method guaranteed to clear up any 
misinterpretation of the questions. In addition, the primary examiner was blinded for 
the allocated treatments during most of the questions, both preoperatively and 12 
months after hysterectomy. In contrast, this method is vulnerable for evaluation of 
patient satisfaction after treatment. The primary examiner might have biased study 
participants when filling out the questionnaires. Therefore, the trials may have 
improved if we had chosen to blind even more of the questions for the primary 
examiner at the outpatient clinic.  
    
9.3 Interpretation of the results 
  The main objective in Paper 1 was to evaluate the long-term effect of removal 
of the endocervix during laparoscopy with a reverse LEEP-technique using the 
Lapcone electrode. This device was developed in order to reduce the occurrence of 
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vaginal bleeding after LSH. The modification of the surgical procedure by excision of 
the endocervix after amputation of the cervix appeared to have no effect on the 
occurrence of vaginal bleeding following LSH compared to the traditionally LSH-
procedure. In spite of our continued effort to improve outcomes after this procedure, 
the results in Paper 1 and 3 showed a relatively high occurrence of vaginal bleeding 12 
months after LSH. There might be other mechanisms of bleeding after LSH than 
remnant endometrial tissue in the upper cervical canal. Possible mechanisms could be 
angiogenesis or regeneration of endometrial tissue in the upper cervical canal. 
However, all bleeding episodes after LSH were minimal and did not affect patient 
satisfaction. This confirms the results from a large retrospective trial by Lieng et al.31 
 There was a significant reduction of cyclic pelvic pain following LSH and TLH 
(Paper 2 and 3). We found no difference in reduction of cyclic pelvic pain 12 months 
after TLH and LSH, respectively. This result is supported by a previous RCT that 
compared these two procedures. In this trial by Morelli et al, written in Italian, all 
study participants experienced a reduction in symptoms of pelvic and back pain, but 
there were no differences between the two allocated treatments groups during two 
years follow-up.79 Another RCT by Flory et al compared outcomes after LSH and 
LAVH, respectively.78 They found a great reduction in pain but no significant 
differences between the allocated treatments were identified six months after surgery. 
The main controversy is to perform LSH in women with a high degree of 
dysmenorrhea or suspected endometriosis and/or adenomyosis. Previous studies have 
demonstrated the risk of pelvic pain after LSH, but none of these trials had an adequate 
control group.31;95;96;107 Both Paper 2 and 3 demonstrated an equal reduction of cyclic 
pelvic pain after LSH for both women with and without endometriosis and 
adenomyosis. In addition, there was no difference between outcomes after TLH and 
LSH when these conditions were compared. Although the number of women included 
in these analysis is low, these results support the view of gynecologists who claim that 
LSH is an adequate procedure for women suffering from benign disorders, regardless 
of the occurrence of cyclic pelvic pain, endometriosis and/or adenomyosis. To secure a 
long-term pain relief and effective treatment of endometriosis, all endometriosis must 
be removed during hysterectomy. The cervix shall only be preserved in cases where 
 50 
this is possible. Furthermore, the results in this trial cannot be adapted to women 
suffering from severe or deep infiltrating endometriosis, as these conditions were not 
included in the trial. Unfortunately, there is a lack of other studies of women with 
pelvic pain, endometriosis and adenomyosis comparing outcomes after different 
methods of MIS hysterectomy. 
 Hysterectomy performed because of benign conditions is usually associated 
with improvement in Qol and high patient satisfaction, especially if the surgical 
method has a low re-admission and complication-rate.5;22;29;31;35;40-42;64;73;78;79;90;156-161  
The trials in this PhD thesis confirmed this general impression of a high patient 
satisfaction and improved Qol after both LSH and TLH, respectively. There is a 
shortage of additional RCTs comparing clinical outcomes following different methods 
of MIS hysterectomies. In contrast, several RCT`s have evaluated outcomes after 
traditional SAH and TAH, respectively.14;17-19;23;24;76;77;82;83 Even at nine-year follow up 
after the procedures, Thakar et al found no long-term differences between these two 
procedures.83 Therefore, the cervix might not play an important role in outcomes after 
hysterectomy.  
 In the Lap-hyst-trial, there was a shorter procedure time for LSH compared to 
TLH. In addition, a tendency of faster recovery, less re-consultations and 
complications after LSH compared to TLH was documented. This confirms results 
from larger retrospective and prospective non-randomised trials.28-30;33;33;35;40;41;63;73;87-
91;105;162 In large gynecological departments, the incidence of vaginal cuff dehiscence 
after TLH is reported to be  < 1%.29;33;163;164 Unfortunately, two women (6.5%) 
experienced this complication in the Lap-Hyst-trial. To thoroughly explore 
complications after TLH and LSH, larger studies must be conducted. Especially, this is 
the case when rare complications like urethral injuries or morcellating of sarcomas in 
anticipated benign conditions are explored.29;33;162 Infrequent complications are mainly 
detectable in large population-based-trials or national registers.10 Therefore, the trials 
included in this PhD thesis cannot strongly conclude regarding difference in 
complications between the assigned treatments.  
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10. CONCLUSIONS AND PERSPECTIVES  
 
10.1 Conclusions 
 
 
1. The excision of the endocervix by a reverse conisation during LSH appears to have 
no effect in terms of reduced bleeding after the procedure compared to the standard 
LSH-technique. Episodes of vaginal bleeding after LSH are relatively common. All 
bleeding episodes after LSH are minor and do not seem to affect patient 
satisfaction. Is it important to inform women of the risk of vaginal bleeding after 
this procedure, preoperatively. Women who are treated with LSH must accept the 
risk of minimal vaginal bleeding after the procedure. If feasible, women who do 
not accept episodes of vaginal bleeding after hysterectomy should be offered VH or 
TLH.  
 
2. There is no difference in occurrence, intensity or reduction of cyclic pelvic pain 12 
months after TLH compared to following LSH. The cyclic pelvic pain is reduced to 
a minimum 12 months after LSH and TLH, respectively. In addition, this relief of 
pain also occur for women with minimal, mild or moderate endometriosis detected 
and treated during the procedure and for women with adenomyosis confirmed in 
the specimen after hysterectomy. There seems to be no difference in reduction of 
cyclic pelvic pain in women with or without perioperative detection of minimal, 
mild or moderate endometriosis and for women with or without histological 
confirmed adenomyosis.  
 
3. Patient satisfaction after LSH and TLH is very high. There is a significant 
improvement in Qol 12 months after both procedures. There are no differences 
between TLH and LSH in the outcomes of patient satisfaction and Qol 12 months 
after the procedures.  
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10.2 Perspectives 
The trials included in this PhD thesis revealed no differences in cyclic pelvic 
pain, patient satisfaction and Qol 12 months after TLH and LSH, respectively. 
Therefore, both procedures should be considered equally successful. The LSH-
procedure has comparable results for women with a high degree of dysmenorrhea, 
endometriosis or adenomyosis compared to TLH. The safest surgical method should 
be preferred, if there are no documented differences in the essential outcomes of  
benign conditions. To evaluate the benefits and risks of the alternative surgical 
treatment options, an individual risk analysis should be presented to the women, 
preoperatively.  
In spite of the current recommendations of using MIS in hysterectomy for 
benign conditions, AH continues to be a frequently used method. Vaginal 
hysterectomy is a preferred option, but this method has some limitations. The TLH-
technique requires more advanced skills for laparoscopic dissection and suturing 
compared to LSH. Therefore, to safely accomplish a total hysterectomy in women with 
fibroids, TAH might be the only manageable technique for many gynecologists. 
Consequently, to avoid laparotomy in such cases, the gynecologist should consider 
performing LSH. A more extent use of LSH may be an important contribution to 
reduce abdominal hysterectomy and fully implement minimal invasive hysterectomy 
worldwide.  
Some challenges and limitations of MIS hysterectomy in benign conditions 
need to be assessed in future studies. There should be a continued focus of reducing 
complications, adverse events and morbidity of the treatment. To address this problem 
properly, there should be a mandatory national register of hysterectomy and 
laparoscopic procedures. In such a register, methods and equipment used must be 
registered. At current date, the Norwegian Society for Gynaecology and Obstetrics has 
a voluntary register for endoscopic gynaecological surgery.165 On the basis of the 
current evidence regarding methods of hysterectomy, I recommend the Norwegian 
Board of Health Supervision to make this register compulsory for all hysterectomies 
performed in Norway.  
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Furthermore, at current date there are no perfect methods for tissue extraction 
during LSH. Gynecologists should work to improve the method for a safe and practical 
way to extract the specimen during LSH.  
Although bleeding after LSH does not seem to affect patient satisfaction, 
gynecologists should be encouraged to improve the method of LSH in order to avoid 
unnecessary bleeding episodes after the procedure. There are several possible 
mechanisms for bleeding after LSH that needs to be clarified. 
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Abstract 
Objective: To compare reduction of cyclic pelvic pain, patient satisfaction and quality of life 
(Qol) after total laparoscopic hysterectomy (TLH) and laparoscopic supracervical 
hysterectomy (LSH) in premenopausal women suffering from dysmenorrhea. 
Design: Randomised blinded controlled trial.  
Setting: Norwegian university teaching hospital. 
Sample: Sixty-two women with dysmenorrhea on a basis of a benign condition.  
Methods: The study participants were randomised to either TLH (n = 31) or LSH (n= 31). 
Main outcome measures: The main outcome measure was reduction of cyclic pelvic pain 12 
months after hysterectomy measured by a visual analogue scale (VAS), range 0-10. 
Secondary outcome measures were patient satisfaction (VAS, range 0-10) and Qol (Short 
Form 36, range 0-100). 
Results: The mean preoperative cyclic pelvic pain in the two treatment groups of TLH and 
LSH was 6.6 (2.4) and 6.8 (2.0), respectively (p=0.70). The mean reduction of this pain 12 
months after TLH was 5.8 (SD 2.6) compared to 6.0 (SD 2.6) after LSH, p=0.77. The mean 
patient satisfaction was 9.3 (1.5) and 9.1 (SD 1.2) 12 months after TLH and LSH, respectively 
(p=0.66). The Qol improved in both allocated treatment groups 12 months after hysterectomy, 
p<0.01. The mean Qol-score 12 months after TLH and LSH was 81.6 (SD 17.8) and 80.2 (SD 
18.0), respectively (p=0.56).  
Conclusion: The reduction of cyclic pelvic pain 12 months after TLH and LSH were 
comparable. The study participants in the two allocated treatment groups had a similar 
improvement in Qol and seemed to be equally satisfied with the treatment 12 months after the 
procedures. 
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Introduction 
The technique for hysterectomy has been debated throughout the last century. The 
controversies have mostly been related to diversity in surgical approach and removal of the 
cervix in women with benign gynecological disorders.1-15 When performing hysterectomy, 
there is an indisputable recommendation to avoid laparotomy by using minimal invasive 
surgery (MIS) techniques.16-18 If vaginal hysterectomy is not feasible the laparoscopic 
approach is recommend.16-18 Most hysterectomies include removal of the cervix, but the rate 
of subtotal hysterectomy in women with benign conditions requiring hysterectomy has 
increased.19-30 Laparoscopic supracervical hysterectomy (LSH) has for the last decade been 
the preferred method for hysterectomy in selected cases at our hospital.26;31-36 We perform this 
procedure in premenopausal women with benign conditions and no history of previous 
cervical dysplasia. LSH is associated with high patient satisfaction. The LSH-technique 
demands less advanced skills for laparoscopic dissection and suturing, ensures a faster 
recovery after surgery and a lower risk of perioperative complications compared to total 
laparoscopic hysterectomy (TLH) and laparoscopically assisted vaginal hysterectomy 
(LAVH).22;29;37-44 However, leaving the cervix is debatable.13;16;17;19;31;32;35;43;45-52 A risk of 
persistent pain and repeated surgery after LSH has been documented.30;32;50;51;53;54 
Consequently, many authors have stated that supracervical hysterectomy should not be 
performed in women with endometriosis, pelvic pain or dysmenorrhea.3;30;50;51;54 In contrast, 
other gynaecologists conclude that endometriosis or pelvic pain should not be 
contraindications for performing LSH, unless leaving the cervix compromises the removal of 
endometriosis.32;40;55;56  
The main objectives of surgical treatment in patients who suffer from benign 
conditions are through a safe method to eradicate or reduce symptoms and improve quality of 
life (Qol). Therefore, when outcomes of hysterectomy are studied in benign gynaecological 
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conditions it is vital to evaluate patient satisfaction and Qol. Short Form 36 (SF-36) is a 
validated and well-documented questionnaire for this purpose.57 The literature of outcomes 
following MIS hysterectomies mainly consists of case series and retrospective 
reports.9;18;19;30;48 Consequently, there is a need for randomised controlled trials (RCT) that 
compare long-term clinical outcomes after these procedures. The persistent controversies 
regarding methods of MIS hysterectomies encouraged us to carry out this blinded RCT. The 
objective of this trial was to compare reduction of pelvic pain, patient satisfaction and Qol 12 
months after TLH and LSH, respectively.   
Methods 
This was a blinded, single centre RCT, performed in a Norwegian university hospital. 
The 0-hypothesis of the trial was: there is no significant difference in reduction of cyclic 
pelvic pain following TLH compared with following LSH. The study was conducted in 
accordance with the Declaration of Helsinki and national as well as local regulations. The 
Scientific Advisory Board at Oslo University Hospital (OUS), the Advisory Committee on the 
Protection of Patient Records at OUS and the Regional Committee for Medical Research 
Ethics in eastern and southern Norway approved the trial and the study was registered in 
ClinicalTrials.gov before recruiting study participants.58  
The women were invited to participate and enrolled in the trial at the outpatient clinic. 
Premenopausal women referred to the Department of gynaecology, OUS due to a benign 
condition requiring hysterectomy were eligible for study recruitment. The trial included 
women with preoperative cyclic pelvic pain, defined as premenstrual or dysmenorrhoeal pain. 
The exclusion criteria were women unable to communicate in Norwegian language, previous 
history of cervical dysplasia, cellular changes suggestive of cervical dysplasia or malignancy 
in preoperative cervical smear or atypical hyperplasia or malignancy in endometrial biopsy. In 
addition, women with a substantially enlarged uterus were excluded. This was defined as 
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corpus uteri measured by transvaginal ultrasound of more than 10 or 12 centimetres in 
anterior-posterior or transversal diameter, respectively. Furthermore, women with occurrence 
of pelvic organ prolapse (POP) more than grade 1, menopausal women, women with a 
concomitant condition requiring removal of both ovaries or with preoperative symptoms 
dominated by a non-cyclic chronical pelvic pain and preoperative signs of severe or deep 
infiltrating endometriosis were not included in the trial.59-62 The preoperative classification of 
severe endometriosis was defined as presence of large endometriomas, suspected extensive 
adhesions or kissing ovaries due to endometriosis. Consequently, peritoneal endometriosis or 
endometriosis in the pouch of Douglas was not a contraindication of being included in the 
trial, unless leaving the cervix compromised the removal or destruction of endometriosis. 
Endometriosis diagnosed perioperatively was treated during the procedure by 
electrocoagulation or excision. 
The authors of the study were primarily responsible for recruiting women. A study 
nurse, not otherwise involved in the trial, performed the randomization procedure, using the 
randomization plan generator with permuted blocks.63 The study participants were 
randomised to either TLH (n = 31) or LSH (n = 31). The assigned treatment was concealed in 
numbered envelopes stored in the operating theatre. All recruited women were numbered 
consecutively corresponding to the numbered envelopes. The envelope was not opened until 
general narcosis of the study participant was established. In order to increase the validity of 
the trial, the assigned procedure was blinded for the study participants throughout the follow-
up period. The women and the primary examiner (the first author) were informed of allocated 
treatment after completing the study forms at follow-up 12 months after the procedure. If 
major complications occurred, the study participants and primary examiner were informed of 
the allocated treatment at the time of suspected complication.  
 
 
 7 
The study participants underwent hysterectomy under general intravenous anaesthetic. 
Six experienced endoscopic gynaecologists with assistance from residents performed the 
procedures. All procedures were performed using 10-millimeter 30-degree laparoscopic 
cameras. The Pelosi Mobiliser and Vcare® uterine manipulator by ConMed Endosurgery, 
Utica, NY, United States, were used during LSH and TLH, respectively. The LSH was 
performed in accordance with the standardised operative technique at our department.35 
During TLH, the surgeons individually determined the method and suture for vaginal cuff 
closure. This was either performed by a continuous suture of 0 (3.5 Metric) V-locTM 180 
absorbable polyglyconated or cross-sutures of 0-Polysorb, manufactured by Covidien, Dublin, 
Ireland. All study participants received 1500-milligram of metronidazole and 400-milligram 
doxycycline intravenously during the procedure as a single dose of prophylactic antibiotics. 
The study participants were scheduled for one night admittance before they were discharged 
from the hospital. They were prescribed and recommend taking a sick leave for 18-20 days 
after the procedure. They were advised to avoid sexual intercourse the first eight weeks 
following surgery. If study participants had suspicion of any complications after discharge 
from the hospital, they were informed to contact the department of gynaecology, directly.  
The study participants and the primary study examiner registered most of the outcome 
measures at the outpatient clinic preoperatively and at follow-up 12 months after surgery. A 
written standardised questionnaire was used. Some outcome measures were reported through 
a standardised clinical interview and examination completed by the primary examiner.  
The primary outcome in this the trial was reduction of cyclic pelvic pain 12 months 
after the procedures measured by a visual analogue scale (VAS) with the range 0-10. The 
occurrence and intensity of cyclic pelvic pain was also registered in a four-graded ordinal 
scale (no pain, mild pain, moderate pain or severe pain). After hysterectomy, the cyclic pelvic 
pain was defined as cyclic pelvic pain with or without concomitant vaginal bleeding. Non-
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cyclic pelvic pain was also registered. We used the SF-36 to evaluate Qol.57 Other variables 
registered both preoperative and 12 months after surgery were: amount and type of bleeding 
(cyclic or irregular) measured by VAS (range 0-10) and a five graded ordinal scale, 
occurrence and grade of POP defined by Pelvic Organ Prolapse-Quantification (POP-Q).61 
Further preoperative variables were age, body mass index (BMI), number of previous births, 
indication for hysterectomy, any previous pelvic or abdominal surgery including caesarean 
section, use of Levonorgestrel-releasing intrauterine system (Mirena), any medication or 
other medical conditions and uterine size measured by transvaginal ultrasound (anterior-
posterior diameter and width of corpus uteri). Additional variables 12 months after 
hysterectomy were patient satisfaction measured by VAS (range 0-10) and a five graded 
ordinal scale (dissatisfied, somewhat dissatisfied, neutral, satisfied, very satisfied), return to 
normal activity (days) and any new symptoms. A scrub-nurse recorded the perioperative 
variables (operation time, weight of specimen, perioperative complications and estimated 
blood loss). A nurse at the gynaecological ward registered body temperature, haemoglobin 
(Hb) preoperatively and one day after surgery, length of stay and eventual complications 
before discharge from the hospital. All further contacts (re-consultations and readmissions) 
and minor complications during the 12-month follow-up were registered without disclosing 
the allocated treatment to study participants.  
Cervical cytology and endometrial biopsy preoperatively, histological analysis of 
specimen from the surgical procedure and cervical or vaginal cytology 12 months after 
surgery were registered in the trial after study participants had completed outcomes at follow 
up. A dedicated pathologist analyzed all specimens from the hysterectomies. A cut-off of 2.0 
millimetres dept of invasion of endometrial glands below the basalis layer was used as 
diagnostic criteria for adenomyosis.64-67 To explore potential menopause, the serum levels of 
Oestradiol (E2), Follicle Stimulating Hormone (FSH), Lutein hormone (LH) and anti-
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Mullerian hormone (AMH) were analyzed preoperatively and 12 months after hysterectomy. 
Women lost to follow-up 12 months after hysterectomy were contacted by phone and received 
a letter with a request to have the follow-up consultation together with a second appointment 
for such a consultation.  
The expected mean pain reduction in the LSH group was 3.3 (SD 2.7).35 During 
planning of the trial, there was no available data for the expected reduction of pain after TLH. 
A difference in pain reduction equal to 1 SD was considered to be of clinical importance. The 
test power and level of significance in the trial were set to 90 % and 0.05, respectively. 
Consequently, 62 women were required in the trial. All data were analyzed using SPSS 18.0 
(SPSS Inc., Chicago, IL). Normally distributed continuous data from two study groups were 
analyzed using a two-sided Independent Samples Student t-test and the Paired Samples t-test 
when paired and categorical data were analyzed using Pearson Chi-Square. The Mann-
Whitney U test or Wilcoxon Signed Rank Test were used for non-normally distributed data. 
All analyses were performed and reported according to the principle of intention to treat. The 
trial was conducted according to the CONSORT guidelines.68;69  
Results 
The study participants were included and treated from February 2011 to November 
2012, figure 1. Hysterectomy was not performed in one woman due to other medical reasons. 
Therefore, 61 women received the allocated treatment. The demographic variables and 
intensity of cyclic pelvic pain were equal for the two allocated treatment groups 
preoperatively, table 1. Women lost to follow-up (n=3) did not differ from other study 
participants in demographic characteristics or preoperative cyclic pelvic pain. The main 
indications for hysterectomy were fibroids, dysmenorrhea and abnormal uterine bleeding in 
39 (62.9 %), 14 (22.6 %) and 9 (14.5 %) women, respectively. The perioperative variables 
and histological diagnosis of specimen are shown in table 2. The mean weight of specimens 
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was 187.3 (SD 93.7) grams. LSH had a shorter duration of surgery compared to TLH, p<0.01. 
Endometriosis was equally detected (n=15, 24.6 %) in both allocated treatment groups during 
the surgical procedures. The pathologist diagnosed fibroids and adenomyosis in 49 (80.3 %) 
and 27 (44.3 %) of the specimen, respectively, and 20 women had both conditions.  
There was an equally distribution in severity of cyclic pelvic pain between the 
allocated treatment groups, preoperatively (p=0.69). In total, 28 (90.3%) study participants in 
the TLH- and LSH-group reported the preoperative pain to be moderate or severe. The 
intensity of cyclic pelvic pain was reduced 12 months after hysterectomy, p<0.01 (Table 3). 
The mean reduction of cyclic pelvic pain 12 months after TLH and LSH was 5.8 (SD 2.6) and 
6.0 (2.4) measured by VAS, respectively (p= 0.77). The occurrence of cyclic pelvic pain in 
both allocated treatment groups was reduced to a minimum 12 months after the procedures, 
p<0.01. Consequently, 42 (71.2 %) and 12 (20.3 %) study participants experienced no pain or 
only mild pelvic pain 12 months after the procedures, respectively. In total, reported 10 (32.3 
%) women cyclic pelvic pain 12 months after TLH compared to 7 (25.0 %) women after LSH, 
p=0.54. 
Except for one woman, all study participants were very satisfied (n=51) or satisfied 
(n=7) with the treatment 12 months after hysterectomy. There was no difference in patient 
satisfaction between the two allocated treatment groups 12 months after the procedures, 
p=0.66. The patient satisfaction after TLH and LSH was 9.3 (SD 1.5) and 9.1 (SD 1.2) 
measured by VAS, respectively. Women experiencing cyclic pelvic pain 12 months after LSH 
(n=7) had a lower patient satisfaction compared to women with no pelvic pain (n=21), 
p=0.02. The mean patient satisfaction VAS scores for these two subgroups were 8.0 (SD 1.8) 
and 9.5 (SD 0.7), respectively. The corresponding patient satisfaction VAS scores in women 
with (n=10) or without (n=21) occurrence of cyclic pelvic pain 12 after TLH were and 9.3 
(SD 0.6) and 9.3 (SD 1.7), respectively (p=0.88). 
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 The mean Qol scores 12 months after hysterectomy measured by SF-36 were higher 
compared to the preoperative values for all study participants and for both allocated treatment 
groups, p<0.02. This improvement of Qol scores were confirmed in all eight subgroups of SF-
36, p<0.05. No difference in total Qol-score between TLH and LSH 12 months after the 
procedures was detected, p=0.43. 
Furthermore, there were no differences between the two allocated treatment groups in 
pelvic pain reduction, patient satisfaction or Qol 12 months after hysterectomy for women 
with or without endometriosis and for women with or without adenomyosis, respectively 
(table 4). Study participants with endometriosis detect during surgery reported the same 
intensity of preoperative cyclic pelvic pain compared to women without endometriosis, p = 
0.89. The mean reduction of cyclic pelvic pain by VAS for women with and without 
endometriosis 12 months after hysterectomy was 5.8 (SD 2.2) and 5.9 (SD 2.6), respectively. 
In contrast, study participants with adenomyosis reported higher preoperative cyclic pelvic 
pain (mean 7.7, SD 1.6) compared to women without this diagnosis (mean 6.0, SD 2.4), 
p=0.03. There was a tendency of a greater pelvic pain reduction in women with adenomyosis 
(mean 6.5, SD 2.3) compared to women without this diagnosis (mean 5.3, SD 2.6), p=0.06. 
The mean patient satisfaction 12 months after hysterectomy for women with or without 
endometriosis was 9.2 (SD 0.6) and 9.2 (SD 1.5), respectively (p=0.99). The corresponding 
figures for women with or without adenomyosis were 9.1 (SD 1.7) and 9.3 (SD 0.9), 
respectively (p=0.55).  
No perioperative complications occurred and the perioperative blood loss was 
negligible for all procedures in the trial. Therefore, no difference in blood loss between the 
two treatment groups was detected. The reduction in Hb from the preoperative value 
compared to one day after the procedure was 1.4 (1.0) and 1.4 (0.7) for TLH and LSH, 
respectively (p=0.87). All women stayed for one night in hospital after hysterectomy, except 
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for two women who left the hospital just a few hours after LSH. The women returned to 
normal activity after LSH and TLH within mean 25.8 (SD 11.9) and 35.8 (SD 26.8) days, 
respectively (p=0.15). We found a trend of more re-consultations after discharge from the 
hospital in the TLH-group (n=11), compared to the women who were treated with LSH (n=5), 
p=0.08. In total, six complications were registered during the trial period. There were 5 (16.1 
%) complications subsequent to TLH compared to 1 (3.3 %) after LSH, p=0.11. Three lower 
urinary tract infections were diagnosed and treated within the first month after TLH. In 
addition, three major complications occurred. One woman was diagnosed with an infected 
cervical top hematoma three weeks after LSH. She was readmitted to the hospital and 
successfully treated with antibiotics intravenously. Two women experienced vaginal 
dehiscence three and six months after TLH, respectively. They were both re-operated with 
laparoscopic suture of the vaginal cuff. All three women who suffered from major 
complications were informed about their allocated treatment at the time of suspected 
complication. At 12 months follow-up, they all scored high patient satisfaction, had no cyclic 
pelvic pain and a great improvement in Qol-scores. As expected, we found a higher 
occurrence of vaginal bleeding after LSH compared to TLH, p=0.05. In the LSH group, four 
(14.3%) women had regular and five (17.9%) irregular bleeding, respectively. In the TLH 
group, three (9.7%) women reported irregular vaginal bleeding episodes after the procedure 
and additional two were diagnosed with a non-bleeding granulating polyp in the vaginal top. 
The occurrence of vaginal bleeding did neither affect patient satisfaction nor Qol 12 months 
after hysterectomy. There was an equal distribution of preoperative asymptomatic grade 1 
POP in the TLH- and LSH-group, (p=0.72). This incidence was 5 (16.1%) and 4 (13.3%) in 
each allocated treatment group, respectably. There was a higher incidence of asymptomatic 
grade 1 POP 12 months after TLH (n=10, 32.3%) compared to preoperatively, p=0.03. This 
increase was not found in the LSH-group, as only 5 (17.8%) POP’s were documented 12 
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months after surgery. In addition, no difference between the two allocated treatment groups 
was detected comparing values of FSH, LH, E2 and AMH preoperatively and 12 months after 
hysterectomy. In total, there was a higher level of FSH and LH detected 12 months after 
hysterectomy compared the preoperative values (p=0.02). No comparable changes in E2 and 
AMH were detected.  
Discussion 
Main Findings 
  The main result in this trial was that we found no difference in reduction of cyclic 
pelvic pain 12 months after TLH and LSH. In addition, there were no differences in cyclic 
pelvic pain, patient satisfaction or Qol between the two allocated treatment groups 12 months 
after the procedures. The outcomes subsequent to TLH and LSH were comparable for women 
with or without endometriosis and for women with or without adenomyosis. There was a 
shorter duration of surgery for LSH compared to TLH. In addition, there was a tendency of 
more re-consultations, complications and POP’s following TLH compared to after LSH.    
Strengths and Limitations 
A strong external validity for the primary outcome was taken care of by the 
methodological strength of this blinded RCT. The main weakness of this trial is the number of 
study participants, which limits conclusions beyond the main outcome. Consequently, results 
of subgroup analysis such as clinical outcomes in women with endometriosis and 
adenomyosis in the trial must be interpreted with caution. The prevalence of endometriosis 
and adenomyosis is reported in a wide range (20-60 %) in different studies of 
hysterectomy.66;67;70 We diagnosed these conditions in 24.6 % and 44.3 % of the study 
participants, respectively. If this trial should have been powered for sub-group analysis of 
endometriosis and adenomyosis, a pilot study and additional power analysis should have been 
performed before study start.  
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In addition, the trial had most likely improved if we had used a validated 
endometriosis-scale.59;60;62 Unfortunately, these scales were not systematically in use at our 
department at the time we planned and conducted the trial. Furthermore, the results in this 
trial cannot be adapted in severe or deep infiltrating endometriosis, as these conditions were 
not included in the trial.  
Interpretation 
The main outcome of our trial is supported by a previous RCT written in Italian 
comparing these two procedures.71 Morelli et al randomised 141 women to either TLH or 
LSH. They found no statistical differences between the two allocated treatments groups at two 
years follow-up. In total, experienced 14 (20 %) women pelvic pain 12 months after TLH 
compared to 16 (22 %) after LSH, p=0.71. A complementary RCT has compared LSH with a 
MIS procedure that resembles TLH; the laparoscopically-assisted vaginal hysterectomy 
(LAVH).72 In this trial, Flory et al detected a great reduction in pain, improvement of 
symptoms and psychosocial outcomes six months after the procedures, but no significant 
differences between LAVH (n=32) and LSH (n=31) were identified.  
To perform a large high-quality RCT comparing different methods of hysterectomies 
is costly, time-consuming and therefore rarely conducted.4;6;9;15;71-78 Consequently, there is a 
shortage of additional RCTs comparing methods of MIS hysterectomies.4;9;19;30 A large 
prospective non-randomized trial by Wellwiener et al (n=1952) has reported results in favour 
of LSH in peri- and postoperative outcomes and complication compared to TLH (Wellwiener 
2013).43 This trial is similar with our trial in preoperative demographic, clinical characteristics 
and surgical data. A supplementary prospective non-randomised trial by Einarsson et al 
(n=122) has demonstrated a greater improvement in short-term postoperative Qol after LSH 
compared to TLH measured by SF-36.22 In addition, this trial demonstrated a similar result as 
our trial of more complications and readmissions after TLH compared to LSH. Several RCT`s 
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have evaluated outcomes after traditional supracervical (SCH) or total abdominal 
hysterectomy (TAH), respectively.6;15;28;73;75-78 Even at nine-year follow up after the 
procedures, Thakar et al found no long-term differences between TAH and SCH.78  
Our trial reflects on whether it is acceptable to perform LSH in women with a high 
degree of dysmenorrhea or suspected endometriosis and/or adenomyosis. Although the 
sample size in our study is small, the results indicate that women with cyclic pelvic pain and 
endometriosis and/or adenomyosis achieve symptom relief and improved Qol regardless of 
whether the cervix is removed or not. The result supports findings from an additional 
observational trial from our department.32 This trial, demonstrated a reduction of cyclic pelvic 
pain 12 months after LSH, including for the women with endometriosis or adenomyosis. It is 
important to emphasize that all endometriosis must be removed together with the 
hysterectomy to secure a long-term pain relief and effective treatment of endometriosis. The 
cervix shall only be preserved in cases where this is possible. Furthermore, several 
retrospective studies have demonstrated a risk of pelvic pain after LSH, but none of these 
trials had representative control groups.32;35;50;51;54 Unfortunately, there is a lack of other 
prospective studies including women with pelvic pain, endometriosis and adenomyosis 
comparing outcomes after different methods of hysterectomies.9;19;66  
Conclusion 
In this RCT we found no differences in long-term outcomes of cyclic pelvic pain, 
patient satisfaction and Qol 12 months after TLH compared to LSH. If there are no 
documented differences in the essential outcomes, the safest surgical method should be 
preferred. LSH is fairly easy to accomplish with a lower risk of major complications 
compared to TLH. Consequently, LSH should be a recommended approach for MIS 
hysterectomy in selected cases of women suffering from dysmenorrhea.  
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Table 1: The preoperative demographic data, cyclic pelvic pain and quality of life in the two 
allocated treatment groups.  
 
 
 
Age (years), mean (SD) 
Body mass index, mean (SD) 
Smoking, n (%) 
Number of births, median (range) 
Previous caesarean delivery, n (%) 
Previous operations score, median (range)3 
Previous hysteroscopic resection, n (%)4 
Use of LNG-IUS, n (%)5 
Fibroids detected preoperatively, n (%)6 
Fibroids, largest diameter (cm), mean (SD)6 
Anterior-posterior diameter of corpus uteri, mean (SD)6 
Transversal diameter of corpus uteri, mean (SD)6 
Pelvic organ prolapse grade 1, n (%)7 
Vaginal bleeding (VAS), mean (SD)8 
Cyclic pelvic pain (VAS), mean (SD)8 
Quality of life (SF-36, total score), mean (SD)9 
TLH1 
(n=31) 
45.1 (5.6) 
26.0 (6.1) 
10 (32.3) 
1 (0-4) 
5 (16.1) 
1 (0-4) 
7 (22.6) 
5 (16.1) 
27 (87.1) 
3.4 (1.3) 
5.7 (1.2) 
6.7 (1.0) 
5 (16.1) 
7.4 (2.1) 
6.6 (2.4) 
64.0 (17.4) 
LSH2 
(n=31) 
44.5 (4.2) 
26.3 (5.1) 
14 (45.2) 
1 (0-4) 
7 (22.6) 
1 (0-5) 
6 (19.4) 
6 (19.4) 
22 (71.0) 
4.2 (1.6) 
6.0 (1.3) 
7.0 (1.5) 
4 (13.3) 
8.4 (1.4) 
6.8 (2.0) 
66.3 (21.6) 
p-value 
 
0.62 
0.78 
0.55 
0.52 
0.50 
0.84 
0.76 
0.74 
0.21 
0.42 
0.30 
0.30 
0.72 
0.02 
0.70 
0.56 
1 Total laparoscopic hysterectomy (TLH). 
2 Laparoscopic supracervical hysterectomy (LSH). 
3 Previous operations score, measured by a total score:  
  1 point for each previous laparoscopy and 2 points for each previous laparotomy including caesarean sections.  
4 Hysteroscopic endometrial resection or resection of fibroids. 
5 Levonorgestrel-releasing intrauterine system (LNG-IUS), Mirena. 
6 Measured by vaginal ultrasound. 
7 Pelvic organ prolapse (POP) grade 1, POP-Quantification (POP-Q). 
8 Visual analogue scale (VAS), range 0-10. 
9 Short form 36 (SF-36), Range 0-100. A total score is reported when all questions of SF-36 are completed.  
  This score is reported in allocated groups of TLH (n=29) and LSH (n=31), respectively. 
 
Table 2: Perioperative variables and histological diagnosis of specimen from hysterectomy in 
the two allocated treatment groups.  
 
 
 
Duration of surgery (minutes), mean (SD)3 
Weight of specimen (gram), mean (SD) 
Haemoglobin drop (g/dL), mean (SD)4 
Endometriosis detected during surgery, n (%)5 
Histology sections examined per specimen, mean (SD) 
Adenomyosis in specimen, n (%) 
Fibroids in specimen, n (%) 
TLH1 
(n=31) 
102.7 (27.3) 
180.2 (68.6) 
1.4 (1.0) 
7 (22.6) 
6.2 (2.6) 
15 (48.4) 
26 (83.9) 
LSH2 
(n=30) 
76.0 (25.1) 
194.1(114.8) 
1.4 (0.7) 
8 (26.7) 
5.3 (1.0) 
12 (40.0) 
23 (76.7) 
p-value 
 
< 0.01 
0.56 
0.87 
0.47 
0.11 
0.51 
0.35 
1 Total laparoscopic hysterectomy (TLH) 
2 Laparoscopic supracervical hysterectomy (LSH) 
3 Time from application of the uterine manipulator until completed skin closure. 
4 Difference in Hemoglobin, preoperative value compared to one day after surgery.  
  For two women in the LSH-group, the postoperative value was measured the before discharge day of surgery.  
5 Endometriosis diagnosed during surgery was treated during the procedure by electrocoagulation or excision. 
 
 
Table 3: Outcome measures in the allocated treatment groups 12 months after hysterectomy 
 
 
Cyclic pelvic pain reduction (VAS), mean (SD)3,4 
Cyclic pelvic pain 12 months after hysterectomy (VAS), mean (SD)3 
Cyclic pelvic pain 12 months after hysterectomy, n (%) 
Patient satisfaction 12 months after hysterectomy, mean VAS (SD)3 
Qol 12 months after hysterectomy (SF-36, total score), mean (SD)5 
Qol (SF-36, total score) improvement, mean (SD)5,6 
Pelvic organ prolapse 12 months after hysterectomy, n (%)7 
Occurrence of vaginal bleeding 12 months after hysterectomy, n (%)8 
TLH1  
(n=31) 
5.8 (2.6) 
0.8 (1.6) 
10 (32.3) 
9.3 (1.5) 
81.6 (17.8) 
17.6 (20.0) 
10 (32.3) 
3 (9.7) 
LSH2  
(n=28) 
6.0 (2.6) 
0.8 (2.0) 
7 (25.0) 
9.1 (1.2) 
80.2 (18.0) 
13.9 (26.0) 
5 (17.8) 
9 (32.1) 
p-value 
 
0.94 
0.77 
0.54 
0.43 
0.69 
0.56 
0.23 
0.03 
1 Total laparoscopic hysterectomy (TLH) 
2 Laparoscopic supracervical hysterectomy (LSH) 
3 Visual analogue scale (VAS), Range 0-10. 
4 Cyclic pelvic pain reduction: Preoperative VAS-score minus VAS-score 12 months after surgery. 
5 Quality of life (Qol) by Short form 36 (SF-36), Range 0-100. A total score is reported when all questions of SF-36 are    
  completed. This score is reported in 29 (93.5 %) and 26 (92.3 %) of the TLH- and LSH-group, respectively.  
6 Qol improvement: SF-36-score 12 months after surgery minus SF-36-score preoperatively. 
7 Pelvic organ prolapse (POP) 12 months after hysterectomy by POP-Quantification, all grade 1. 
8 All bleeding episodes were minor, both cyclic and irregular bleeding reported.   
   Irregular bleeding episodes reported in the allocated treatment groups: TLH (n=3) and LSH (n=5).  
 
Table 4: Outcome measures 12 months after hysterectomy in the allocated treatment groups 
for women with and without endometriosis or adenomyosis, respectively. 
  
TLH1 
(n=31) 
LSH2 
(n=30) p-value 
E
N
D
O
M
E
TR
IO
S
 
No endometriosis detected during surgery, n (%) 
Reduction of cyclic pelvic pain (VAS), mean (SD) 3,4 
Cyclic pelvic pain (VAS) 12 months after hysterectomy, mean (SD) 3 
Patient satisfaction (VAS) 12 months after hysterectomy, mean (SD) 3 
Qol (SF-36, total score) 12 months after hysterectomy, mean (SD)5 
24 (77.4) 
5.8 (2.6) 
0.8 (1.6) 
9.3 (1.6) 
83.2 (17.2) 
22 (73.3) 
5.9 (2.7) 
0.8 (2.3) 
9.2 (1.4) 
82.1 (17.3) 
0.71 
0.89 
0.98 
0.86 
0.82 
Endometriosis detected and treated during surgery, n (%) 
Reduction of cyclic pelvic pain (VAS), mean (SD) 3,4 
Cyclic pelvic pain (VAS) 12 months after hysterectomy, mean (SD) 3 
Patient satisfaction (VAS) 12 months after hysterectomy, mean (SD) 3 
Qol (SF-36, total score) 12 months after hysterectomy, mean (SD)5 
7 (22.6) 
5.6 (2.8) 
1.0 (1.5) 
9.4 (0.5) 
78.8 (20.5) 
8 (26.7) 
6.1 (1.5) 
0.8 (1.4) 
9.0 (0.7) 
74.0 (20.2) 
0.71 
0.71 
0.82 
0.26 
0.68 
A
D
E
N
O
M
Y
O
SI
S No adenomyosis in specimen from hysterectomy, n (%) 
Reduction of cyclic pelvic pain (VAS), mean (SD) 3,4 
Cyclic pelvic pain (VAS) 12 months after hysterectomy, mean (SD) 3 
Patient satisfaction (VAS) 12 months after hysterectomy, mean (SD) 3 
Qol (SF-36, total score) 12 months after hysterectomy, mean (SD)5 
16 (51.6) 
4.9 (2.6) 
0.5 (1.2) 
9.5 (0.6) 
83.6 (16.0) 
18 (60.0) 
5.7 (2.6) 
0.6 (2.1) 
9.1 (1.1) 
78.6 (17.1) 
0.51 
0.44 
0.93 
0.22 
0.41 
Adenomyosis detected in specimen from hysterectomy, n (%) 
Reduction of cyclic pelvic pain (VAS), mean (SD) 3,4 
Cyclic pelvic pain (VAS) 12 months after hysterectomy, mean (SD) 3 
Patient satisfaction (VAS) 12 months after hysterectomy, mean (SD)3 
Qol (SF-36, total score) 12 months after hysterectomy, mean (SD)5 
15 (48.4) 
6.6 (2.4) 
1.2 (1.8) 
9.1 (2.0) 
80.6 (20.0) 
12 (40.0) 
6.4 (2.2) 
1.1 (2.1) 
9.2 (1.4) 
82.4 (19.6) 
0.51 
0.74 
0.94 
0.88 
0.82 
1 Total laparoscopic hysterectomy (TLH) 
2 Laparoscopic supracervical hysterectomy (LSH) 
3 Visual analogue scale (VAS), Range 0-10.  
4 Cyclic pelvic pain reduction: preoperative VAS-score minus VAS-score 12 months after surgery. 
5 Quality of life (Qol) by Short form 36 (SF-36), Range 0-100. A total score is reported when all questions of SF-36  
  are completed. This score is reported in 29 (93.5 %) and 26 (92.3 %) of the TLH- and LSH-group, respectively. 
 
